Nano Dimension (NNDM) 20-F 11 Mar 21 2020 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document Information Line Items
Entity Registrant Name	Nano Dimension Ltd.
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	172,063,020
Amendment Flag	false
Entity Central Index Key	0001643303
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Annual Report	true
Document Shell Company Report	false
Document Transition Report	false
Entity Incorporation, State or Country Code	L3
Entity Interactive Data Current	Yes

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets
Cash	$ 585,338	$ 3,894
Bank deposits	85,596
Restricted deposits	62	31
Trade receivables	713	1,816
Other receivables	1,126	570
Inventory	3,314	3,543
Total current assets	676,149	9,854
Restricted deposits	406	377
Property plant and equipment, net	5,092	4,743
Right of use assets	3,169	2,673
Intangible assets	4,440	5,211
Total non-current assets	13,107	13,004
Total assets	689,256	22,858
Liabilities
Trade payables	776	850
Other payables	5,910	3,575
Total current liabilities	6,686	4,425
Liability in respect of government grants	850	1,044
Lease liability	2,618	2,089
Liability in respect of warrants	11,986	3,698
Total non-current liabilities	15,454	6,831
Total liabilities	22,140	11,256
Equity
Share capital	257,225	6,441
Share premium and capital reserves	518,426	65,202
Treasury shares	(1,509)	(1,509)
Presentation currency translation reserve	1,431	1,431
Accumulated loss	(108,457)	(59,963)
Total equity	667,116	11,602
Total liabilities and equity	$ 689,256	$ 22,858

Consolidated Statements of Prof

Consolidated Statements of Profit or Loss and Other Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Profit or loss [abstract]
Revenues	$ 3,399	$ 7,070	$ 5,100
Cost of revenues	1,563	4,312	3,594
Cost of revenues - amortization of intangible	771	772	772
Total cost of revenues	2,334	5,084	4,366
Gross profit	1,065	1,986	734
Research and development expenses, net	9,878	8,082	8,623
Sales and marketing expenses	6,597	5,469	4,259
General and administrative expenses	20,287	3,270	3,002
Operating loss	(35,697)	(14,835)	(15,150)
Finance income	446	8,765	54
Finance expense	13,243	2,283	392
Total comprehensive loss	$ (48,494)	$ (8,353)	$ (15,488)
Basic and diluted loss per share (USD) (after 1:50 reverse split effective June 29, 2020, see also note 11A) (in Dollars per share)	$ (1.13)	$ (2.38)	$ (8.40)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Share capital	Share premium and capital reserves	Treasury shares	Presentation currency translation reserve	Accumulated loss	Total
Balance at beginning at Dec. 31, 2017	$ 2,307	$ 52,059	$ (1,509)	$ 1,431	$ (36,122)	$ 18,166
Loss for the year					(15,488)	(15,488)
Issuance of Ordinary Shares, net	981	11,490				12,471
Exercise of warrants and options	3	(3)
Share-based payments		423				423
Balance at ending at Dec. 31, 2018	3,291	63,969	(1,509)	1,431	(51,610)	15,572
Loss for the year					(8,353)	(8,353)
Issuance of Ordinary Shares, net	2,216	(633)				1,583
Exercise of warrants, options and conversion of convertible notes	934	1,421				2,355
Share-based payments		445				445
Balance at ending at Dec. 31, 2019	6,441	65,202	(1,509)	1,431	(59,963)	11,602
Loss for the year					(48,494)	(48,494)
Issuance of Ordinary Shares, net	244,511	405,604				650,115
Exercise of warrants, options and conversion of convertible notes	6,273	1,450				7,723
Share-based payments		46,170				46,170
Balance at ending at Dec. 31, 2020	$ 257,225	$ 518,426	$ (1,509)	$ 1,431	$ (108,457)	$ 667,116

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flow from operating activities:
Net loss	$ (48,494)	$ (8,353)	$ (15,488)
Depreciation	2,658	2,666	1,943
Financing expenses (income), net	(60)	2,035	412
Revaluation of financial liabilities accounted at fair value	12,825	(8,707)
Loss from disposal of property plant and equipment		18	537
Share-based payments	20,501	439	402
Profit loss	35,924	(3,549)	3,294
Changes in assets and liabilities:
Decrease (increase) in inventory	229	(442)	(1,410)
Decrease (increase) in other receivables	(556)		13
Decrease (increase) in trade receivables	1,103	(503)	(1,219)
Increase in other payables	2,247	718	287
Increase (decrease) in trade payables	(99)	(555)	1,134
Decrease in other long-term liabilities			(58)
Changes in assets and liabilities	2,924	(782)	(1,253)
Net cash used in operating activities	(9,646)	(12,684)	(13,447)
Cash flow from investing activities:
Investment in bank deposits	(85,500)
Interest received	152
Change in restricted bank deposits	(60)	(40)	86
Acquisition of property plant and equipment	(1,359)	(601)	(1,319)
Proceeds from sale of property plant and equipment	4		1
Net cash used in investing activities	(86,763)	(641)	(1,232)
Cash flow from financing activities:
Proceeds from issuance of Ordinary Shares, warrants and convertible notes, net	676,133	14,367	12,471
Exercise of warrants and options	2,837	282
Lease payments	(1,118)	(1,095)
Amounts recognized in respect of government grants liability, net	(126)	(113)	9
Net cash provided by financing activities	677,726	13,441	12,480
Increase (decrease) in cash	581,317	116	(2,199)
Cash at beginning of the year	3,894	3,753	6,103
Effect of exchange rate fluctuations on cash	127	25	(151)
Cash at end of year	585,338	3,894	3,753
Non-cash transactions:
Property plant and equipment acquired on credit	25		$ 9
Conversion of convertible notes and warrants to equity	$ 4,886	$ 2,073

General

General	12 Months Ended
	Dec. 31, 2020
Disclosure of general hedge accounting [Abstract]
General	Note 1 General A. Reporting Entity Nano Dimension Ltd. (the “Company”) is an Israeli resident company incorporated in Israel. The address of the Company’s registered office is 2 Ilan Ramon St., Ness Ziona, Israel. The consolidated financial statements of the Company as of December 31, 2020, comprise the Company and its subsidiaries in Israel, in the United States, and in Hong Kong (together referred to as the “Group”). The Company engages, by means of the subsidiary Nano Dimension Technologies Ltd. (“Nano-Technologies”), in the development of a three-dimensional (“3D”) additive manufacturing system and nanotechnology based conductive and dielectric inks, which are supplementary products to the additive manufacturing system. Since March 2016, the Company’s American Depositary Shares (“ADSs”) have been trading on the Nasdaq Capital Market. The Ordinary Shares of the Company were registered for trade on the Tel Aviv Stock Exchange (TASE). On May 20, 2020, the Company voluntary delisted its Ordinary Shares from the TASE. B. Since August 25, 2014, the Company has devoted substantially all of its financial resources to develop its products and has financed its operations primarily through the issuance of equity securities. The amount of the Company’s future net profits or losses will depend, in part, on the rate of its future expenditures, its ability to generate significant revenues from the sale of its products, and its ability to obtain funding through the issuance of securities, strategic collaborations or grants. Starting in the fourth quarter of 2017, the Group began to commercialize its products and has generated revenues, mainly from sales of its 3D printers. The Group’s ability to generate revenue and achieve profitability depends on its ability to successfully commercialize its products. C. Equity Offerings During 2020, the Company conducted several public offerings in the United States, with aggregate gross proceeds of approximately $710,000,000, before deducting underwriting discounts and commissions and other offering-related expenses. After the reporting period, the Company conducted additional public offerings in the United States, with aggregate gross proceeds of $833,000,000, before deducting underwriting discounts and commissions and other offering-related expenses. D. Effect of the coronavirus pandemic on the Group's business Following the outbreak of the coronavirus (COVID-19) in China in December 2019, and it reaching many other countries as well at the beginning of 2020, there was a decrease in economic activity in many areas around the world, including Israel, the U.S., Europe and Asia-Pacific. The spread of the virus has led, inter alia, to a decrease in global transportation, restrictions on travel and work that were announced by the State of Israel and other countries around the world. As a result of the COVID-19 pandemic’s global effects, many entities held off on capital expenses; thus, the Company witnessed a significant decrease in the Group's revenues during 2020. Since this event is not under the control of the Group, the Group is continuing to regularly follow the changes on the markets in Israel and the world and is examining the mid- and long-term effects on the business results of the Group. E. The Operating Cycle The operating cycle period of the Group is 12 months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 Summary of Significant Accounting Policies The accounting policies of the Group set out below have been applied consistently for all periods presented in these consolidated financial statements, and have been applied consistently by Group entities, except for the change in accounting policy from January 1, 2019 as described in note 2.O below. A. Basis for presentation of the financial statements The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The consolidated financial statements have been prepared on the historical cost basis, except when otherwise indicated. The consolidated financial statements were authorized for issuance by the Company’s board of directors on March 10, 2021. B. Use of estimates and judgments The preparation of financial statements in conformity with IFRS as issued by the International Accounting Standards Board requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The preparation of accounting estimates used in the preparation of the Group’s financial statements requires management of the Company to make assumptions regarding circumstances and events that involve considerable uncertainty. Management of the Company prepares the estimates on the basis of past experiences, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Below is information about significant assumptions made by the Group with respect to estimates and judgments: - Fair value measurement of financial instruments The Company accounts for financial liabilities relating to convertible notes, warrants and related derivatives at fair value through profit or loss. The fair values of these instruments are determined by using the Monte Carlo simulation method and the Black-Scholes model and assumptions regarding unobservable inputs used in the valuation model including the probability of meeting revenue targets, and weighted average cost of capital, all of which can lead to profit or loss from a change in the fair value of these instruments. For information on details regarding fair value measurement at Level 2 and sensitivity analysis see Note 18.D regarding financial instruments. - Share-based payment transactions Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model, including the expected life of the share option and volatility and making assumptions about them. For the measurement of the fair value of equity-settled transactions at the grant date, the Company uses the Black-Scholes formula or the Binomial pricing model. C. Basis of consolidation Subsidiaries A subsidiary is an entity controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of the subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control is lost. The accounting policies of the subsidiaries are aligned with the policies adopted by the Group. D. Functional currency and presentation currency (1) Functional and presentation currency These consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s functional currency, and have been rounded to the nearest thousands, except when otherwise indicated. The USD is the currency that represents the principal economic environment in which the Company operates. (2) Foreign currency transactions Transactions in currencies other than the U.S. dollar are translated to the functional currency of the Group at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Foreign currency differences arising on translation are recognized in profit or loss. (3) Index linked financial items Financial assets and liabilities which according to their terms are linked to changes in the Israeli Consumer Price Index (the “Index”) are adjusted according to the relevant Index on every reporting date in accordance with the terms of the agreement. Linkage differences deriving from said adjustment are recorded to profit and loss. (4) Below are details regarding the exchange rate of the New Israeli Shekel (“NIS”) and the Euro and the Index of the NIS: Consumer Price Index Euro NIS December 31, 2020 101.1 1.22 0.31 December 31, 2019 101.8 1.12 0.29 December 31, 2018 101.2 1.14 0.27 Change in percentages: Year ended December 31, 2020 (0.69 ) (9.32 ) (2 ) Year ended December 31, 2019 0.6 (2 ) 8.45 ) Year ended December 31, 2018 0.8 (4.4 ) (7.5 E. Financial instruments (1) Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes trade receivables on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset were transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: amortized cost; fair value through other comprehensive income – investments in debt instruments; fair value through other comprehensive income – investments in equity instruments; or fair value through profit or loss. The Group does not expect to incur any credit loss, thus the financial statements do not include provision for expected credit loss. All financial assets not classified as measured at amortized cost or fair value through other comprehensive income as described above, as well as financial assets designated at fair value through profit or loss, are measured at fair value through profit or loss. On initial recognition, the Group designates financial assets at fair value through profit or loss if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise. The Group has balances of cash, trade and other receivables and deposits that are held within a business model whose objective is collecting contractual cash flows. The contractual cash flows of these financial assets represent solely payments of principal and interest that reflect consideration for the time value of money and the credit risk. Accordingly, these financial assets are measured at amortized cost. Cash includes cash balances available for immediate use. Deposits include short-term deposits with banking corporations (with original maturities of three months or more) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. (2) Non-derivative financial liabilities Non-derivative financial liabilities include trade and other payables. Initial recognition of financial liabilities The Group initially recognizes financial liabilities on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Transaction costs directly attributable to an expected issuance of an instrument that will be classified as a financial liability are recognized as an asset in the framework of deferred expenses in the statement of financial position. These transaction costs are deducted from the financial liability upon its initial recognition, or are amortized as financing expenses in the statement of profit or loss and other comprehensive income when the issuance is no longer expected to occur. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged or cancelled. Offset of financial instruments Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Measurement of derivative financial instruments Derivatives are recognized initially at fair value attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognized in profit or loss, as financing income or expense. F. Property plant and equipment Property plant and equipment are presented according to cost, including directly attributed acquisition costs, minus accumulated depreciation and losses from accrued decrease in value. Improvements and upgrades are included in the assets’ costs whereas maintenance and repair costs are recognized in profit and loss as accrued. Gains and losses on disposal of a fixed asset item are determined by comparing the net proceeds from disposal with the carrying amount of the asset, and are recognized in their corresponding section, in profit or loss. The cost of printers used for internal purposes, which are classified as property, plant and equipment, includes the cost of materials and direct labor, and any other costs directly attributable to bringing the assets to a working condition for their intended use. The depreciation is calculated in equal yearly rates during the period of the useful life span of the assets, as follows: % Machinery and equipment (mainly 7%) 7 – 25 Computers 20 – 33 Office furniture and equipment 7 – 15 Leasehold Improvements 7 – 10 Printers leased to customers 25 Depreciation methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate. G. Inventory Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the weighted averages method, and includes expenditure incurred in acquiring the inventories and the costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, cost includes an appropriate share of production overheads based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. H. Impairment of non-financial assets The carrying amounts of the Group’s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. The recoverable amount of an asset is the greater of its value in use and its fair value, minus the costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the assessments of market participants regarding the time value of money and the risks specific to the asset, for which the estimated future cash flows from the asset were not adjusted. An impairment loss is recognized if the carrying amount of an asset exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. I. Provisions A provision for claims is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably and it is probable that an outflow of economic benefits will be required to settle the obligation. When the value of time is material, the provision is measured at its present value. J. Treasury shares and Ordinary Shares When share capital recognized as equity is repurchased by the Group, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity, and the resulting surplus on the transaction is carried to share premium, whereas a deficit on the transaction is deducted from retained earnings. Ordinary Shares are classified as equity. Incremental costs directly attributable to the issuance of Ordinary Shares and share options are recognized as a deduction from equity, net of any tax effects. K. Revenue recognition The Company recognizes revenue when the customer obtains control over the promised goods or services. The revenue is measured according to the amount of the consideration to which the Company expects to be entitled in exchange for the goods or services promised to the customer, other than amounts collected for third parties. The Company accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Company can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Company can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Company is entitled to in exchange for the goods or services transferred to the customer, will be collected. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Company has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. On the contract’s inception date, the Company assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer goods or services (or a bundle of goods or services) that are distinct. The Company identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Company’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. The Company’s identified performance obligations include: printer, ink, maintenance (which is generally provided for a period of up to one year), training and installation. Revenue is allocated among performance obligations in a manner that reflects the consideration that the Company expects to be entitled to for the promised goods based on the standalone selling prices (“SSP”) of the goods or services of each performance obligation. SSP are estimated for each distinct performance obligation and judgment may be required in their determination. The best evidence of SSP is the estimated price of a product or service if the Company would sell them separately in similar circumstances and to similar customers. The Company allocates the transaction price to the identified performance obligations based on the residual approach, while allocating the estimated standalone selling prices for performance obligations relating to maintenance, training and installation services, and the residual is allocated to the printer. Revenues allocated to the printers, installation and training, and ink and other consumables are recognized when the control is passed in accordance with the contract terms at a point in time. Maintenance revenue is recognized ratably, on a straight-line basis, over the period of the services. Revenue from training and installation is recognized during the time of performance. A contract asset is recognized when the Group has a right to consideration for goods or services it transferred to the customer that is conditional on other than the passing of time, such as future performance of the Group. Contract assets are classified as receivables when the rights in their respect become unconditional. A contract liability is recognized when the Group has an obligation to transfer goods or services to the customer for which it received consideration (or the consideration is payable) from the customer. L. Research and development and intangible assets Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use. In the fourth quarter of 2016, the Group ceased to capitalize development expenses and began to amortize the intangible asset arising from capitalization of development expenses, upon the initiation of its beta program. In subsequent periods, capitalized development expenditure is measured at cost minus accumulated amortization and accumulated impairment losses. M. Amortization of intangible assets Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset, minus its residual value. Amortization is recognized in profit or loss on a straight-line basis, over the estimated useful lives of the intangible assets from the date they are available for use, since these methods most closely reflect the expected pattern of consumption of the future economic benefits embodied in each asset. The estimated useful lives of the capitalized development costs have been determined by the Company’s management as 10 years. Amortization methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate. N. Government grants Government grants are recognized initially at fair value when there is reasonable assurance that they will be received and the Group will comply with the conditions associated with the grant. Grants from the Israeli Innovation Authority (the “Innovation Authority”), with respect to research and development projects, are accounted for as forgivable loans according to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. Grants received from the Innovation Authority are recognized as a liability according to their fair value on the date of their receipt, unless it is reasonably certain, on that date, that the amount received will not be refunded. The amount of the liability is reexamined each period, and any changes in the present value of the cash flows discounted at the original interest rate of the grant are recognized in profit or loss. The difference between the amount received and the fair value on the date of receiving the grant is recognized as a deduction of research and development expenses. Expenses related to revaluation of the liability in respect of government grants were recognized in the statements of profit or loss and other comprehensive income as finance expenses. O. Leases Policy applicable before January 1, 2019 Determining whether an arrangement contains a lease At inception or upon reassessment of an arrangement, the Group determines whether such an arrangement is or contains a lease. An arrangement is a lease or contains a lease if the following two criteria are met: ● The fulfilment of the arrangement is dependent on the use of a specific asset or assets; and ● The arrangement contains rights to use the asset. Leases that do not transfer substantially all the risks and rewards incidental to ownership of an underlying asset were classified as operating leases. The Group recognized operating lease payments as expenses on a straight-line basis over the lease term. Policy applicable from January 1, 2019 Determining whether an arrangement contains a lease On the inception date of the lease, the Group determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, the Group assesses whether it has the following two rights throughout the lease term: (a) The right to obtain substantially all the economic benefits from use of the identified asset; and (b) The right to direct the identified asset’s use. For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, the Group elected to account for the contract as a single lease component without separating the components. Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-of-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group’s leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-of-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The Group has elected to apply the practical expedient by which short-term leases of up to one year and/or leases in which the underlying asset has a low value, are accounted for such that lease payments are recognized in profit or loss on a straight-line basis, over the lease term, without recognizing an asset and/or liability in the statement of financial position. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Variable lease payments Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-of-use asset. Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs. Depreciation of right-of-use asset After lease commencement, a right-of-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever is earlier, as follows: ● Buildings 1-5 years ● Motor vehicles 3 years Reassessment of lease liability Upon the occurrence of a significant event or a significant change in circumstances that is under the control of the Group and had an effect on the decision whether it is reasonably certain that the Group will exercise an option, which was not included before in the lease term, or will not exercise an option, which was previously included in the lease term, the Group re-measures the lease liability according to the revised leased payments using a new discount rate. The change in the carrying amount of the liability is recognized against the right-of-use asset, or recognized in profit or loss if the carrying amount of the right-of-use asset was reduced to zero. Lease modifications When a lease modification increases the scope of the lease by adding a right to use one or more underlying assets, and the consideration for the lease increased by an amount commensurate with the stand-alone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the contract’s circumstances, the Group accounts for the modification as a separate lease. In all other cases, on the initial date of the lease modification, the Group allocates the consideration in the modified contract to the contract components, determines the revised lease term and measures the lease liability by discounting the revised lease payments using a revised discount rate. For lease modifications that decrease the scope of the lease, the Group recognizes a decrease in the carrying amount of the right-of-use asset in order to reflect the partial or full cancellation of the lease, and recognizes in profit or loss a profit (or loss) that equals the difference between the decrease in the right-of-use asset and re-measurement of the lease liability. For other lease modifications, the Group re-measures the lease liability against the right-of-use asset. P. Financing income and expenses Financing income is comprised of interest income on deposits, revaluation of liability in respect of government grants, foreign currency gains and fair value changes of financial liabilities through profit and loss. Financing expenses are comprised of bank fees, exchange rate differences, revaluation of liability in respect of government grants and fair value changes of financial liabilities through profit and loss. Foreign currency gains and losses on financial assets and financial liabilities are reported on a net basis as either financing income or financing expenses depending on whether foreign currency movements are in a net gain or net loss position. Q. Employee benefits Severance pay The Group’s liability for severance pay for its employees is calculated pursuant to Israeli Severance Pay Law (1963) (the “Severance Pay Law”). The Group’s liability is covered by monthly deposits with severance pay funds and insurance policies. For all of the Group’s employees, the payments to pension funds and to insurance companies exempt the Group from any obligation towards its employees, in accordance with Section 14 of the Severance Pay Law, which is accounted for as a defined contribution plan (as defined below). Accumulated amounts in pension funds and in insurance companies are not under the Group’s control or management and, accordingly, neither those amounts nor the corresponding accrual for severance pay are presented in the consolidated statements of financial position. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Share-based payment arrangements in which the subsidiary grants rights to parent company equity instruments to its employees are accounted for by the Group as equity-settled share-based payment transactions. R. Loss per share The Group presents basic and diluted loss per share for its Ordinary Shares. Basic loss per share is calculated by dividing the loss attributable to holders of Ordinary Shares of the Company by the weighted average number of Ordinary Shares outstanding during the year, adjusted for treasury shares. Diluted loss per share is determined by adjusting the loss attributable to holders of Ordinary Shares of the Company and the weighted average number of Ordinary Shares outstanding, after adjustment for treasury shares, for the effects of all dilutive potential Ordinary Shares.

Cash and Restricted Deposits

Cash and Restricted Deposits	12 Months Ended
	Dec. 31, 2020
Disclosure Of Cash And Restricted Deposits Explanatory [Abstract]
Cash and Restricted Deposits	Note 3.A Cash December 31, 2019 2020 Thousands Thousands Bank accounts- dominated in NIS 348 1,057 Bank accounts- dominated in USD 3,536 584,205 Bank accounts- other 10 76 3,894 585,338 Note 3.B Restricted deposits The Group has a restricted deposit in the amount of $468 thousand for the lease of its offices and labs and for credit cards. The deposit is not linked and bears an annual interest rate of 0.01%. The Group expects to lease its offices and labs for a period of more than a year, thus the restricted deposit was classified as a non-current asset.

Trade Receivables and Other Rec

Trade Receivables and Other Receivables	12 Months Ended
	Dec. 31, 2020
Trade and other receivables [Abstract]
Trade receivable and Other receivables	Note 4.A Trade receivables December 31, 2019 2020 Thousands Thousands Open balances 1,816 713 Note 4.B Other receivables December 31, 2019 2020 Thousands Thousands Government authorities 332 400 Prepaid expenses 221 696 Others 17 30 570 1,126

Inventory

Inventory	12 Months Ended
	Dec. 31, 2020
Inventory [Abstract]
Inventory	Note 5 Inventory December 31, 2019 2020 Thousands Thousands Raw materials and work in progress (*) 2,636 2,692 Finished goods 907 622 3,543 3,314 (*) A part of the raw materials and work in progress are expected to be sold in a period longer than the operating cycle of the Company.

Property Plant and Equipment, N

Property Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property, plant and equipment [Abstract]
Property plant and equipment, net	Note 6 Property plant and equipment, net Machinery and equipment Computers Office furniture and equipment Leasehold improvements Printers leased to clients Total Thousands Thousands Thousands Thousands Thousands Thousands Cost As of January 1, 2019 4,132 471 158 1,719 199 6,679 Additions 770 5 32 26 - 833 Disposals (306 ) - (3 ) - (87 ) (396 ) Designation change 112 - - - (112 ) - As of December 31, 2019 4,708 476 187 1,745 - 7,116 Additions 1,163 124 85 12 - 1,384 Disposals - (8 ) (22 ) - - (30 ) As of December 31, 2020 5,871 592 250 1,757 - 8,470 Depreciation accrued As of January 1, 2019 792 365 37 238 47 1,479 Disposals 799 65 17 166 13 1,060 Designation change (133 ) - (1 ) - (32 ) (166 ) Disposals 28 - - - (28 ) - As of December 31, 2019 1,486 430 53 404 - 2,373 Additions 787 47 30 167 - 1,031 Disposals - (8 ) (18 ) - - (26 ) As of December 31, 2020 2,273 469 65 571 - 3,378 Carrying amount As of December 31, 2020 3,598 123 185 1,186 - 5,092 As of December 31, 2019 3,222 46 134 1,341 - 4,743 During the year ended December 31, 2020, the Group acquired $25,000 of property plant and equipment on credit.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2020
Intangible Assets [Abstract]
Intangible assets	Note 7 Intangible assets Intangible assets include development costs that were capitalized. The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use. See also Note 2.M. 2019 2020 Thousands Thousands Balance as of January 1 5,983 5,211 Amortization (772 ) (771 ) Balance as of December 31 5,211 4,440

Subsidiaries

Subsidiaries	12 Months Ended
	Dec. 31, 2020
Subsidiaries [Abstract]
Subsidiaries	Note 8 Subsidiaries Presented hereunder is a list of the Group’s subsidiaries: Principal location The Group’s ownership interest in the subsidiary for the year ended December 31 2019 2020 Name of company % % Nano Dimension Technologies Ltd. Israel 100 % 100 % Nano Dimension IP Ltd. (*) Israel 100 % 100 % Nano Dimension USA Inc. USA 100 % 100 % Nano Dimension (HK) Limited (*) Asia-Pacific 100 % 100 % (*) Nano Dimension IP Ltd. and Nano Dimension (HK) Limited were incorporated by the Company in 2018. Nano Dimension IP Ltd. had no material activity until and during 2020.

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2020
Other Payables [Abstract]
Other payables	Note 9 Other payables December 31, 2019 2020 Thousands Thousands Accrued expenses 406 1,635 Contract liabilities 991 968 Lease liability 1,055 1,148 Employees and related liabilities 616 1,230 Government authorities 249 659 Current maturities in respect of government grants 231 226 Others 27 44 3,575 5,910

Liability in Respect of Governm

Liability in Respect of Government Grants	12 Months Ended
	Dec. 31, 2020
Liability in Respect of Government Grants [Abstract]
Liability in respect of government grants	Note 10 Liability in respect of government grants 2019 2020 Thousands Thousands Balance as of January 1 1,445 1,275 Amounts received during the year 121 55 Payment of royalties (185 ) (158 ) Amounts recognized as an offset from research and development expenses (49 ) (23 ) Revaluation of the liability (57 ) (73 ) Balance as of December 31 1,275 1,076 Current maturities in respect of government grants 231 226 Long term liability in respect of government grants 1,044 850 During the years 2014 to 2020, Nano-Technologies received several approvals from the Innovation Authority, to finance development projects in an aggregate amount of up to $4,505,000, while the Innovation Authority share of financing the aforesaid amount was in a range of 30% to 50% of expenditures. As of December 31, 2020, the Company received grants in the aggregate amount of $1,865,000. In consideration, Nano-Technologies undertook to pay the Innovation Authority royalties in the rate of 3%-3.5% of the future sales up to the amount of the grants received. On the date on which the grants were received, the Group recognized a liability using a discount rate ranging between 19% to 30%.

Equity

Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Equity	Note 11 Equity A. The Company’s share capital (in thousands of Ordinary Shares) Ordinary Shares 2019(*) 2020 Issued and paid-up share capital as at December 31 4,179 172,052 Authorized share capital 10,000 250,000 (*) Following the approval of its shareholders on April 16, 2020, the board of directors of the Company approved a 1-for-50 reverse split of the Company’s share capital. The implementation of the reverse split resulted in a reduction in the issued and outstanding Ordinary Shares, and the increase of the par value per Ordinary Share from NIS 0.10 to NIS 5.00 per Ordinary Share. Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares to each of the Company’s ADSs, such that its ratio of ADSs to Ordinary Shares has changed from one (1) ADS representing fifty (50) Ordinary Shares to a new ratio of one (1) ADS representing one (1) Ordinary Share. The effective date of this reverse split was June 29, 2020. All options and warrants of the Company outstanding immediately prior to the reverse split were appropriately adjusted by dividing the number of Ordinary Shares into which the options and warrants are exercisable by 50 and multiplying the exercise price thereof by 50, as a result of the reverse split. All the figures in these financial statements relating to share capital were appropriately adjusted to reflect the above-mentioned reverse split. Share capital (in thousands of shares of NIS 5 par value) Ordinary Shares 2019 2020 Issued as at January 1 1,931 4,179 Issued for cash during the period 1,600 163,542 Conversion into shares of convertible notes during the period 610 1,395 Exercise of warrants during the period 38 2,918 Exercise of share options during the period - 18 Issued and paid-in share capital as at December 31 4,179 172,052 In April 2020, following approval of the general meeting of the Company’s shareholders, the Company increased its authorized share capital by NIS 100,000,000, such that the authorized share capital of the Company was NIS 150,000,000. In May 2020, following approval of the general meeting of the Company’s shareholders, the Company increased its authorized share capital by NIS 100,000,000, such that the authorized share capital of the Company was NIS 250,000,000. In June 2020, following approval of the general meeting of the Company’s shareholders, the Company increased its authorized share capital by NIS 1,000,000,000, such that the authorized share capital of the Company was NIS 1,250,000,000 divided into 250,000,000 Ordinary Shares, par value NIS 5.00 each. After the reporting date, on February 2021, following approval of the general meeting of the Company’s shareholders, the Company increased its authorized share capital by NIS 1,250,000,000, such that the authorized share capital of the Company was NIS 2,500,000,000 divided into 500,000,000 Ordinary Shares, par value NIS 5.00 each. B. Financing transactions 1. In February 2019, the Company issued, pursuant to a public offering in the United States, an aggregate of 1,600,000 ADSs, 1,600,000 non-tradable warrants with an exercise price of $8.625 per ADS and term of 5 years and 1,200,000 non-tradable rights to purchase shares with an exercise price of $7.50 per ADS and term of 6 months. In certain cases, the rights to purchase and the warrants may be exercised on a cashless basis. Therefore, the rights to purchase and the warrants are accounted for as derivative instruments which are classified as a liability and measured at fair value through profit or loss. The total gross consideration was $12,000,000 and was initially attributed to the financial liability for the rights to purchase and warrants based on their fair value in the amount of $10,201,000 and the remaining amount was attributed to the ADSs issued and recognized as an equity component in the amount of $1,799,000. Applicable issuance costs, amounting to $1,440,000, have been allocated in the same proportion as the allocation of the gross proceeds. An amount of $1,224,000 was considered as issuance costs allocated to the rights to purchase and the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ADSs in the amount of $216,000 have been recorded in equity as a reduction of the share premium. The total net proceeds from the offering were approximately $10,560,000. During the first quarter of 2019, investors exercised 37,620 of the rights to purchase 37,620 Ordinary Shares for a total consideration of $282,000. The value of the financial liability in respect to the warrants was measured as of December 31, 2020, at an amount of approximately $10,892,000. 2. In August 2019, the Company issued, pursuant to a securities purchase agreement, convertible promissory notes, in an aggregate principal amount of $4,276,000 and an additional approximately $2,700,000 to be received in two subsequent closings, bringing the expected total gross proceeds from this funding to approximately $7,000,000. The notes were convertible into the Company’s ADSs. As a part of this transaction, the Company issued non-tradable warrants to purchase 62,668,850 ADSs. The warrants have an exercise price equal to 125% of the conversion price of the convertible promissory notes, will be exercisable upon the six-month anniversary of issuance and will expire five years from the date of issuance. The total gross proceeds from the first closing were $4,276,000. The first tranche of the convertible promissory notes was unsecured, had a maturity date of March 4, 2021, bore no interest except in an event of default and could be converted, at the election of the holder, into ADSs at an initial per share conversion price of $2.90, subject to adjustments, including among others, revenue targets and the conversion prices of the subsequent tranches. The convertible notes have been designated as a financial liability measured at fair value through profit and loss since they were combined instruments including embedded derivatives. The warrants are also classified as a financial liability that is measured at fair value through profit and loss as neither the exercise price nor the number of shares to be issued is fixed. The rights for the future issuance of the convertible notes and the warrants of the second and third tranches have been accounted for as derivatives. The initial fair value of the financial liabilities issued in the transaction at their issuance date has been evaluated in the amount of $11,609,000, while the consideration received from this transaction was $4,276,000. The difference, in the amount of $7,333,000, has been allocated to the convertible notes, warrants and rights to purchase recognized with respect to this transaction. The allocation was based on the proportion of the fair value of each instrument. The loss that has not been recognized for each instrument is amortized on a straight line basis over the term of each instrument. Accordingly, from the consideration received, approximately $1,569,000 was attributed to the convertible notes of the first tranche, $1,902,000 was attributed to the warrants of the first tranche, and a total of approximately $805,000 was attributed to the rights with respect to the second and third tranches. During 2019 and until December 31, 2019, $1,767,400 of the principal amount of the convertible notes was converted into 609,448 ADSs. As a result of the conversion, $2,003,000 of the loss that had not been initially recorded has been recognized as finance expenses in the year ended December 31, 2019. Prior to February 4, 2020, an additional of approximately $204,000 of the principal amount of the convertible notes was converted. On February 4, 2020, the Company and the holders of a significant portion of the remaining financial instruments agreed to amend the terms of this transaction such that the conversion price of the convertible notes decreased to $1.74 per ADS, and the holders of such notes agreed to convert such notes into ADSs. As a result, an aggregate of approximately $2,305,000 of the principal amount of the convertible notes was converted. Additionally, the Company agreed to amend the exercise price of the warrants of the first tranche to $1.914 per ADS, and the Company and the investors agreed to terminate substantially all remaining obligations in this transaction, including the instruments to be issued under the second and third tranche. During the first quarter of 2020, all the outstanding balance of the convertible notes was converted. The fair value of the remaining financial liabilities relating to the warrants issued in this transaction was measured as of December 31, 2020, at an amount of approximately $745,000. See also Note 18.D - Financial Liabilities. 3. During 2020, the Company issued, pursuant to several public offerings in the United States, an aggregate of 163,542,447 ADSs and 430,000 pre-funded warrants (that were converted to ADSs during 2020). The total gross proceeds from the offerings were approximately $710,013,000, before deducting underwriting discounts and commissions and other offering-related expenses. The total net proceeds from the offerings, after deducting issuance expenses, were approximately $650,115,000. As a part of those offerings, the Company issued a total of 7,365,289 non-tradable warrants to the underwriters. The warrants are accounted for as share-based payment expenses, see also note 17. 4. See also Note 21.A regarding public offerings after the reporting date. C. Treasury shares As of December 31, 2020, the Company held 10,540 Ordinary Shares, constituting approximately 0.006% of its issued and paid up share capital.

Revenues

Revenues	12 Months Ended
	Dec. 31, 2020
Revenues [Abstract]
Revenues	Note 12 Revenues For the year ended 2018 2019 2020 Thousands Thousands Thousands Consumables 190 650 554 Support services 400 598 654 Sales of printers 4,320 5,770 2,191 Total 4,910 7,018 3,399 Printers rental 190 52 - Total revenue 5,100 7,070 3,399 Revenues per geographical locations: For the year ended 2018 2019 2020 Thousands Thousands Thousands U.S. 2,727 3,367 1,263 Asia Pacific 1,239 1,591 1,362 Europe and Israel(*) 1,134 2,112 774 Total revenue 5,100 7,070 3,399 (*) The Company combined all revenues into the Europe and Israel geography, due to immateriality of the amounts. Timing of revenue recognition: For the year ended 2018 2019 2020 Thousands Thousands Thousands Goods and services transferred over time 590 650 654 Goods transferred at a point in time 4,510 6,420 2,745 Total revenue 5,100 7,070 3,399 The table below provides information regarding receivables, contract assets and contract liabilities deriving from contracts with customers. December 31, 2019 2020 Thousands Thousands Open balances 1,816 713 Contract liabilities 991 968 The contract liabilities primarily relate to the advance consideration received from customers for contracts giving yearly maintenance for the printer. The revenue is recognized in a straight line basis over the contracts’ period. Contract costs Management expects that commissions paid to agents for obtaining contracts are recoverable. The Group applies the expedient included in IFRS 15.94 and recognizes incremental costs for obtaining the contract as an expense as incurred, where the amortization period of the asset it would have otherwise recognized is one year or less. During 2020, the Company witnessed a significant decrease in its revenues due to the effects of the COVID-19 pandemic. See also note 1.D.

Cost of Revenues

Cost of Revenues	12 Months Ended
	Dec. 31, 2020
Disclosure of cost of sales [text block] [Abstract]
Cost of revenues	Note 13 Cost of revenues For the year ended 2018 2019 2020 Thousands Thousands Thousands According to sources of revenue - Consumables 195 240 169 Support services 403 855 629 Sales of printers 2,938 3,192 765 Printers rental 58 25 - Total 3,594 4,312 1,563

Further Detail of Profit or Los

Further Detail of Profit or Loss	12 Months Ended
	Dec. 31, 2020
Profit or loss [abstract]
Further detail of profit or loss	Note 14 Further detail of profit or loss For the year ended 2018 2019 2020 Thousands Thousands Thousands A. Research and development expenses, net Payroll 4,890 4,834 6,531 Materials 1,065 1,001 940 Subcontractors 70 82 258 Patent registration 70 144 160 Depreciation 880 1,534 1,588 Rental fees and maintenance 908 197 173 Other 782 339 249 8,665 8,131 9,899 Less – government grants (42 ) (49 ) (21 ) 8,623 8,082 9,878 B. Sales and marketing expenses Payroll 2,226 2,873 5,326 Marketing, advertising and commissions 1,381 1,808 577 Rental fees and maintenance 64 114 201 Travel abroad 201 317 235 Depreciation 186 212 223 Other 201 145 35 4,259 5,469 6,597 C. General and administrative expenses Payroll 819 (*) 872 (*) 1,377 Share based payment expenses 206 (*) 155 (*) 16,837 Fees 32 22 22 Professional services 1,114 1,358 1,064 Directors pay 209 (*) 187 (*) - Office expenses 311 359 386 Travel abroad 45 37 44 Depreciation - 78 76 Rental fees and maintenance 91 43 46 Other 107 159 435 3,002 3,270 20,287 D. Finance income Revaluation of liability in respect of government grants - 58 75 Exchange rate differences - - 123 Revaluation of financial liabilities at fair value through profit or loss (**) - 8,707 - Bank interest and fees 54 - 248 54 8,765 446 Finance expense Exchange rate differences 127 151 - Bank fees - 14 28 Finance expense in respect of lease liability - 425 390 Revaluation of financial liabilities at fair value through profit or loss (**) - - 12,825 Fundraising expenses - 1,693 - Revaluation of liability in respect of government grants 265 - - 392 2,283 13,243 (*) Reclassified. (**) See Note 11.B regarding financing transactions that included issuance of financial instruments accounted at fair value through profit and loss.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2020
Income Tax [Abstract]
Income Tax	Note 15 Income Tax A. Corporate tax rate Presented hereunder are the tax rates relevant to the Company in the years 2018 to 2020: 2018 – 23% 2019 – 23% 2020 – 23% On December 22, 2016, the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, the corporate tax rate would be reduced from 25% to 23% in two steps. The first step will be to a rate of 24% as from January 2017 and the second step will be to a rate of 23% as from January 2018. As a result of the reduction in the tax rate, the deferred tax balances as at December 31, 2019 and 2020 were calculated according to the new tax rates specified in the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018), at the tax rate expected to apply on the date of reversal. B. Benefits under the Law for the Encouragement of Industry (Taxes) (a) The Company and some of its subsidiaries qualify as “Industrial Companies” as defined in the Law for the Encouragement of Industry (Taxes) – 1969, and accordingly they are entitled to benefits, of which the most significant are, under limited conditions, the possibility of submitting consolidated tax returns with related Israeli companies and amortization in three equal annual portions of issuance expenses when registering shares for trading as from the date the shares of the company were registered. (b) The Company and certain subsidiaries are submitting a consolidated tax return to the tax authorities in accordance with the Law for the Encouragement of Industry (Taxes) – 1969. As a result, the companies are, inter alia, entitled to offset their losses from the taxable income of other companies, subject to compliance with certain conditions. C. Theoretical tax The following presents the adjustment between the theoretical tax amount and the tax amount included in the financial statements: For the year ended 2018 2019 2020 Thousands Thousands Thousands Total comprehensive loss (15,488 ) (8,353 ) (48,494 ) Statutory tax rate 23 % 23 % 23 % Theoretical tax benefit (3,562 ) (1,921 ) (11,154 ) Increase in tax liability due to: Non-deductible expenses 280 75 4,299 Losses and benefits for tax purposes for which no deferred taxes were recorded 3,282 1,846 6,855 Taxes on income - - - D. Tax assessments The Company has final tax assessments until and including the 2017 tax year. Nano Dimension Technologies Ltd. has final tax assessments until and including the 2015 tax year. E. Accumulated losses for tax purposes and other deductible temporary differences As of the reporting date, the Group has net operating loss for tax purposes in the amount of approximately $79,688,000 and capital loss for tax purpose in the amount of approximately $840,000. As of December 31, 2020, the Group has deductible temporary differences in the amount of approximately $31,634,000, mainly relating to funding expenses and research and development expenses which are deductible over a period of three years for tax purposes. The Group has not recognized a tax asset for the aforesaid losses and deductible temporary differences, due to the uncertainty regarding the ability to utilize those losses and deductible of temporary differences in the future. E. Income Tax Regulations (Rules on Bookkeeping by Foreign Invested Companies and Certain Partnerships and Determination of their Taxable Income), 1986 As a “Controller Foreign Cooperation” (as defined in the Israeli Law for the Encouragement of Capital Investments-1959), the Company's management has elected to apply Income Tax Regulations (Rules for Maintaining Accounting Records of Foreign Invested Companies and Certain Partnerships and Determining Their Taxable Income) – 1986, from January 2018. Accordingly, its taxable income or loss is calculated in US Dollars.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2020
Earnings per share [Abstract]
Loss per share	Note 16 Loss per share For the year ended 2018(*) 2019(*) 2020 Weighted average of number of Ordinary Shares used in the calculation of basic and diluted loss per share (in thousands)(*) 1,836 3,513 42,947 Net loss used in calculation (thousands USD) 15,488 8,353 48,494 In 2020, 22,810,291 options and warrants (in 2019: 3,468,948 and 2018: 170,341) were excluded from the diluted weighted average number of Ordinary Shares calculation as their effect would have been anti-dilutive. (*) All the figures in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A. Weighted average number of Ordinary Shares: Year ended 2018(*) 2019(*) 2020 Thousands Thousands Thousands shares of shares of shares of par value par value par value Balance as at January 1 1,240 1,932 4,179 Effect of share options exercised 1 135 9 Effect of warrants exercised - - 1,184 Effect of conversion of notes - - 1,236 Effect of shares issued during the year 595 1,446 36,339 Weighted average number of Ordinary Shares used to calculate basic and diluted earnings (loss) per share as at December 31 1,836 3,513 42,947 (*) All the figures in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A.

Share-Based Payment

Share-Based Payment	12 Months Ended
	Dec. 31, 2020
Share-Based Payment [Abstract]
Share-based payment	Note 17 Share-based payment A. During 2018, the Company granted to employees, a consultant and officers 2,652,500 non-tradable share options, which are exercisable into 2,652,500 Ordinary Shares. The share options vest over a period of one to three years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date in consideration for an exercise price ranging between $0.28 to $1.59 for each share option. Some of the share options include a cashless exercise mechanism. During 2019, the Company granted to employees, officers and consultants 6,029,000 non-tradable share options, which are exercisable into 6,029,000 Ordinary Shares. The share options vest over a period of three years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date in consideration for an exercise price ranging between $0.14 to $0.17 for each share option. Some of the share options include a cashless exercise mechanism. During 2019, the Company granted to employees 2,723,500 restricted shares units (“RSUs”). The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period of three years. During 2020, the Company granted to employees, officers and consultants 5,400,000 non-tradable share options, which are exercisable into 5,400,000 Ordinary Shares. The share options vest over a period of three years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date in consideration for an exercise price ranging between $0.70 to $4.12 for each share option. Some of the share options include a cashless exercise mechanism. During 2020, the Company granted to employees 1,530,000 RSUs. The RSUs represents the right to receive Ordinary Shares at a future time and vest over a period of three years. During 2020, the Company granted to underwriters in public offerings in the U.S. an aggregate of 7,365,289 warrants, which are exercisable into 7,365,289 Ordinary Shares. The exercise prices range between $0.875 to $9.375 for each warrant. The warrants are exercisable 6 months from the issuance date, and expire 5 years after the issuance date. B. In January 2018, the Company issued non-tradable share options to purchase 300,000 Ordinary Shares to directors of the Company at an exercise price of $1.59 per share. The share options will vest in 12 equal quarterly batches over a period of three years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date. 275,000 of the share options include a cashless exercise mechanism. In July 2019, the Company issued non-tradable share options to purchase 2,545,000 Ordinary Shares to directors of the Company at an exercise price of $0.15 per share. One third of the share options will vest after one year from the grant date, and the remaining will vest in eight equal quarterly batches over a period of two years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date. In July 2020, the Company issued non-tradable share options to purchase 440,000 Ordinary Shares to directors of the Company at an exercise price of $0.70 per share. The share options are vested over a period of no more than 3 years from the grant date. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date. In December 2019, the Company signed an agreement for options grants in January 2, 2020 to purchase 286,172 ADSs with Yoav Stern, the Company’s Chief Executive Officer (“CEO”) and President, with an exercise price of $2.86 per ADS. The vesting start date of the share options is January 2, 2020. In March 2020, the Company issued options to purchase 294,828 ADSs to Yoav Stern, the Company’s CEO and President, with an exercise price of $1.09 per ADS. 99.9% of the options vest at the grant date, and the remaining options will vest 3 years after the grant date. In August 2020, following the approval of our shareholders, in consideration for his services as the Company’s President and CEO, and as appropriate incentive, the Company entered into a private placement of warrants (the “Stern Transaction”) with its CEO and President, Mr. Yoav Stern. In consideration of $150,000, the Company issued to Mr. Stern warrants to purchase 6,880,402 ADSs of the Company. The warrants have an exercise price of $0.75 per ADS, will vest over a period of two and a half years and will expire after 7 years. Simultaneously with the issuance of the warrants, Mr. Stern forfeited options to purchase 581,000 ADSs, previously granted to him, as described above. In addition, as long as Mr. Stern is employed by the Company or is a member of the Company’s board of directors, Mr. Stern may invest an additional amount up to $50,000 to buy Series B Warrants, in an amount equal to 10% of the Company’s fully diluted capital. The exercise price per ADS under the Series B Warrants will be the average of the daily volume weighted average price of the ADSs for the 10 consecutive trading days ending on the trading day that is immediately prior to the date of the applicable notice to purchase the Series B Warrants. The grant of the warrants was treated as a modification of the terms of equity-classified share based payment under IFRS 2. The fair value of the grant was measured at the grant date in an amount of approximately $18.7 million, and is recorded as share-based compensation expenses through the vesting period. In the same general meeting that approved the Stern Transaction, the Company’s shareholders approved the amended terms of compensation of the Company’s CEO and President. After the reporting date, in January 2021, Mr. Stern exercised 30% of the series A warrants. In September 2020, the Company issued 1,500,000 warrants to purchase 1,500,000 ADSs to the Company’s director, Mr. Yaron Eitan, in consideration of $150,000. The warrants have an exercise price of $2.25 per ADS, will vest over a period of three years and will expire after 7 years. C. The fair value of share options is measured using the Black-Scholes formula or the Binomial pricing model. Measurement inputs include the share price on the measurement date, the exercise price of the instrument, expected volatility (based on the weighted average volatility of the Company’s shares, over the expected term of the options), expected term of the options (based on general option holder behavior and expected share price), expected dividends, and the risk-free interest rate (based on government debentures). The following is the data used in determining the fair value of the share options granted: 17.A- 17.B- Number of share options granted 14,638,264 8,942,202 (*) Fair value in the grant date (thousands USD) 43,979 23,434 Range of share price (USD) 0.74-89.83 1.38-94.64 Range of exercise price (USD) 0-114.77 0.7-92.04 Range of expected share price volatility 40.3%-104.96 % 53.75-104.96 % Range of estimated life (years) 4-9 4-7 Range of weighted average of risk-free interest rate 0.36-1.98 % 0.88%-1.32 % Expected dividend yield - - Outstanding as of December 31, 2020 12,603,828 8,839,482 Exercisable as of December 31, 2020 880,734 8,679,113 (*) The options granted to directors and the CEO do not include the series B warrants which the CEO is entitled to purchase, since the number of those warrants is not yet determined. D. The number of share options and RSUs granted to employees and consultants, and included in Note 17.A are as follows: 2019(*) 2020 Outstanding at January 1 112,944 521,138 Granted during the year 461,223 14,295,289 Exercised during the year (24 ) (1,703,902 ) Forfeited or expired during the year (53,005 ) (508,697 ) Outstanding at December 31 521,138 12,603,828 Exercisable as of December 31 53,831 880,734 The number of share options granted to directors and the CEO included in Note 17.B are as follows: 2019 2020 Outstanding at January 1 41,400 78,435 Granted during the year 50,900 8,820,402 Exercised during the year - - Forfeited or expired during the year (13,865 ) (59,355 ) Outstanding at December 31 78,435 8,839,482 Exercisable as of December 31 40,275 8,679,113 E. The share-based payments expenses in 2020 were $20,502,000 (in 2019: $445,000). In addition, the fair value of the warrants granted to underwriters in 2020 were $25,718,000 and has been recorded as a deduction of share premium.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2020
Financial Instruments [Abstract]
Financial instruments	Note 18 Financial instruments A. Risk management policy The actions of the Group expose it to various financial risks, such as a market risk (including a currency risk, fair value risk regarding interest rate and price risk), credit risk, liquidity risk and cash flow risk for the interest rate. The comprehensive risk-management policy of the Group focuses on actions to limit the potential negative impacts on financial performance of the Group to a minimum. The Group does not typically use derivative financial instruments in order to hedge exposures. Risk management is performed by the Group’s CEO in accordance with the policy approved by the board of directors. B. Credit risk The Group does not have a significant concentration of credit risks. The cash of the Group is deposited in Israeli and U.S. banking corporations. In the estimation of the Group’s management, the credit risk for these financial instruments is low. In the estimation of the Group’s management, it does not have any expected credit losses. C. Currency risk A currency risk is the risk of fluctuations in a financial instrument, as a result of changes in the exchange rate of the foreign currency. The following is the classification and linkage terms of the financial instruments of the Group (in thousands USD): NIS Linked to the U.S. dollar Linked to the Euro and other Total December 31, 2020 Cash 1,057 584,205 76 585,338 Bank deposits - 85,596 - 85,596 Restricted deposits 406 62 - 468 Trade receivables 17 534 162 713 Other receivables 410 19 - 429 1,890 670,416 238 672,544 Financial liabilities at amortized cost 4,366 16,134 45 20,545 Total net financial assets (liabilities) (2,476 ) 654,282 193 651,999 December 31, 2019 Cash 348 3,536 10 3,894 Restricted deposits 377 31 - 408 Trade receivables - 1,586 230 1,816 Other receivables 342 - - 342 1,067 5,153 240 6,460 Financial liabilities at amortized cost 4,503 6,740 13 11,256 Total net financial assets (liabilities) (3,436 ) (1,587 ) 227 (4,796 ) The following is a sensitivity analysis of changes in the exchange rate of the NIS as of the reporting date: Profit (loss) Thousands Increase at a rate of 5% (124 ) Increase at a rate of 10% (248 ) Decrease at a rate of 5% 124 Decrease at a rate of 10% 248 D. Fair value of financial instruments December 31, 2020 Level 1 Level 2 Level 3 Total Thousands Thousands Thousands Thousands Financial liabilities: Warrants - 11,636 - 11,636 Financial derivatives - 350 - 350 Total - 11,986 - 11,986 December 31, 2019 Level 1 Level 2 Level 3 Total Thousands Thousands Thousands Thousands Financial liabilities: Warrants - 793 1,364 2,157 Convertible notes - - 1,223 1,223 Financial derivatives - - 318 318 Total - 793 2,905 3,698 Details regarding fair value measurement at Level 2 The fair value of the warrants was measured using the Black-Scholes model. The following inputs were used to determine the fair value: Expected term of warrant (1) – 3.1-3.68 years. Expected volatility (2) – 118.77%-128.1%. Risk-free rate (3) – 0.17%.-0.24% Expected dividend yield – 0%. (1) Based on contractual terms. (2) Based on the historical volatility of the Company’s Ordinary Shares and ADSs. (3) Based on traded zero-coupon U.S. treasury bonds with maturity equal to expected terms. E. Liquidity risk The table below presents the repayment dates of the Group’s financial liabilities based on the contractual terms in undiscounted amounts: First year More than a year Total Thousands Thousands Thousands December 31, 2020 Trade payables 776 - 776 Other payables 5,910 - 5,910 Lease liabilities - 2,618 2,618 Liability in respect of government grants - 850 850 6,686 3,468 10,154 December 31, 2019 Trade payables 850 - 850 Other payables 3,547 28 3,575 Lease liabilities - 2,089 2,089 Liability in respect of government grants - 1,044 1,044 4,397 3,161 7,558

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	Note 19 Leases The Group applies IFRS 16 as from January 1, 2019. The Group has lease agreements with respect to the following items: 1. Offices, labs and manufacturing facilities 2. Vehicles Information regarding material lease agreements a. The Group leases vehicles for three-year periods from several different leasing companies and from time to time changes the number of leased vehicles according to its current needs. The leased vehicles are identified by means of license numbers and the vehicle’s registration, with the leasing companies not being able to switch vehicles, other than in cases of deficiencies. The leased vehicles are used by the Group’s headquarter staff, marketing and sales persons and other employees whose employment agreements include an obligation of the Group to put a vehicle at their disposal. The Group accounted for the arrangement between it and the leasing companies as a lease arrangement in the scope of IFRS 16 and for the arrangement between it and its employees as an arrangement in the scope of IAS 19, Employee Benefits. The agreements with the leasing companies do not contain extension and/or termination options that the Group is reasonably certain to exercise. A lease liability in the amount of $106,000 and right-of-use asset in the amount of $91,000 have been recognized in the statement of financial position as at December 31, 2020 in respect of leases of vehicles. b. The Group leases offices in Ness- Ziona from Africa-Israel for a period of five years under a few different contracts for three different floors used for offices, labs and manufacturing facilities, at the same building. The contractual periods of the aforesaid lease agreements end in August 2021, August 2024 and December 2023. The Group has an option to extend two of the lease agreements for an additional five years for an additional monthly fee (10% increase). The Company expects to extend the lease agreement ended in August 2021 for an additional five years. The Group also leases offices in Hong-Kong. The contractual period of the aforesaid lease agreement ended in February 2021. The Group also leases offices in the U.S. for a contractual period of three years, which ends in August 2023. A lease liability in the amount of $3,660,000 and right-of-use asset in the amount of $3,078,000 have been recognized in the statement of financial position as at December 31, 2020 in respect of leases of offices. Right of use assets: Buildings Vehicles Total Thousands Thousands Thousands Balance as at January 1, 2019 1,687 204 1,891 Depreciation 706 136 842 Additions 1,525 99 1,624 Balance as at January 1, 2020 2,506 167 2,673 Depreciation 740 116 856 Disposals - 69 69 Additions 1,312 109 1,421 Balance as at December 31, 2020 3,078 91 3,169 During the year ended December 31, 2020 and 2019, the Company paid a total of $1,118 thousands and $1,095 thousands, respectively, for lease payments. See also note 14 regarding finance expenses in respect of lease liability. Maturity analysis of the Group’s lease liabilities: December 31, Thousands Less than one year 1,148 One to five years 2,618 Total 3,766 Current maturities of lease liability 1,148 Long-term lease liability 2,618

Transactions and balances with

Transactions and balances with related parties	12 Months Ended
	Dec. 31, 2020
Transactions and balances with related parties [Abstract]
Transactions and balances with related parties	Note 20 Transactions and balances with related parties A. Balances with related parties December 31, 2019 2020 Thousands Thousands Other payables 130 207 B. Shareholders and other related parties benefits Year ended on December 31, 2018 2019 2020 Thousands Thousands Thousands Salaries and related expenses- related parties employed by the Group 829 1,047 18,252 (*) Number of related parties 4 4 5 Compensation for directors not employed by the Group 311 218 2,204 Number of directors 7 6 6 (*) Includes share-based payment expenses of $16,666,000, see note 17.B regarding warrants issued to the CEO. C. On November 20, 2017, the board of directors of the Company approved a non-exceptional transaction in which Mr. Avi Reichental, a then director of the Company, has a personal interest, for open innovation and show room agreements between Nano Dimension USA Inc. and XponentialWorks Inc. and Techniplas, LLC, whereby the Company will lease space and use sales and marketing services in favor of the customer experience center in Ventura, CA, as well as establish cooperation in the field of car electronics starting on December 1, 2017. In March 2019, the Company ceased the obligations with XponentialWorks Inc. and Techniplas. LLC. D. On November 12, 2019, the board of directors of the Company approved an arms-length transaction in which Mr. Ofir Baharav, the former chairman of the board of directors of the Company, has a personal interest, for an administrative services agreement between Nano Dimension USA Inc. and Breezer Holdings LLC, whereby the Company will lease space and will use logistics services for the Company’s office in Boca Raton, Florida, starting on February 1, 2020. In September 2020, the Company ceased this transaction. E. On December 5, 2019, the Company announced the appointment of Yoav Stern as CEO and President, effective January 2, 2020. See note 17.B regarding options granted to the CEO. F. On July 7, 2020, following approval of the general meeting of the Company’s shareholders, the Company granted options to purchase 1,000,000 ADSs to officer and additional 440,000 ADSs and directors of the Company at an exercise price of $0.70 per ADS. G. On July 7, 2020, the Company issued warrants to the Company’s President and CEO, Mr. Yoav Stern. See note 17.B. H. In August 2020, the Company issued warrants to the Company’s director, Mr. Yaron Eitan, see note 17.B

Events after the reporting date

Events after the reporting date	12 Months Ended
	Dec. 31, 2020
Disclosure of non-adjusting events after reporting period [Abstract]
Events after the reporting date	Note 21 Events after the reporting date A. After the reporting period, in January and February 2021, the Company issued, pursuant to two public offerings in the United States, an aggregate of 74,100,000 Ordinary Shares and 1,137,500 non-tradable warrants to the underwriters. The total gross proceeds from the offerings were approximately $833,000,000, before deducting underwriting discounts and commissions and other offering-related expenses.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis for presentation of the financial statements	A. Basis for presentation of the financial statements The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The consolidated financial statements have been prepared on the historical cost basis, except when otherwise indicated. The consolidated financial statements were authorized for issuance by the Company’s board of directors on March 10, 2021.
Use of estimates and judgments	B. Use of estimates and judgments The preparation of financial statements in conformity with IFRS as issued by the International Accounting Standards Board requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The preparation of accounting estimates used in the preparation of the Group’s financial statements requires management of the Company to make assumptions regarding circumstances and events that involve considerable uncertainty. Management of the Company prepares the estimates on the basis of past experiences, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Below is information about significant assumptions made by the Group with respect to estimates and judgments: - Fair value measurement of financial instruments The Company accounts for financial liabilities relating to convertible notes, warrants and related derivatives at fair value through profit or loss. The fair values of these instruments are determined by using the Monte Carlo simulation method and the Black-Scholes model and assumptions regarding unobservable inputs used in the valuation model including the probability of meeting revenue targets, and weighted average cost of capital, all of which can lead to profit or loss from a change in the fair value of these instruments. For information on details regarding fair value measurement at Level 2 and sensitivity analysis see Note 18.D regarding financial instruments. - Share-based payment transactions Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model, including the expected life of the share option and volatility and making assumptions about them. For the measurement of the fair value of equity-settled transactions at the grant date, the Company uses the Black-Scholes formula or the Binomial pricing model.
Basis of consolidation Subsidiaries	C. Basis of consolidation Subsidiaries A subsidiary is an entity controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of the subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control is lost. The accounting policies of the subsidiaries are aligned with the policies adopted by the Group.
Functional currency and presentation currency	D. Functional currency and presentation currency (1) Functional and presentation currency These consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s functional currency, and have been rounded to the nearest thousands, except when otherwise indicated. The USD is the currency that represents the principal economic environment in which the Company operates. (2) Foreign currency transactions Transactions in currencies other than the U.S. dollar are translated to the functional currency of the Group at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Foreign currency differences arising on translation are recognized in profit or loss. (3) Index linked financial items Financial assets and liabilities which according to their terms are linked to changes in the Israeli Consumer Price Index (the “Index”) are adjusted according to the relevant Index on every reporting date in accordance with the terms of the agreement. Linkage differences deriving from said adjustment are recorded to profit and loss. (4) Below are details regarding the exchange rate of the New Israeli Shekel (“NIS”) and the Euro and the Index of the NIS: Consumer Price Index Euro NIS December 31, 2020 101.1 1.22 0.31 December 31, 2019 101.8 1.12 0.29 December 31, 2018 101.2 1.14 0.27 Change in percentages: Year ended December 31, 2020 (0.69 ) (9.32 ) (2 ) Year ended December 31, 2019 0.6 (2 ) 8.45 ) Year ended December 31, 2018 0.8 (4.4 ) (7.5
Financial instruments	E. Financial instruments (1) Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes trade receivables on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset were transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: amortized cost; fair value through other comprehensive income – investments in debt instruments; fair value through other comprehensive income – investments in equity instruments; or fair value through profit or loss. The Group does not expect to incur any credit loss, thus the financial statements do not include provision for expected credit loss. All financial assets not classified as measured at amortized cost or fair value through other comprehensive income as described above, as well as financial assets designated at fair value through profit or loss, are measured at fair value through profit or loss. On initial recognition, the Group designates financial assets at fair value through profit or loss if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise. The Group has balances of cash, trade and other receivables and deposits that are held within a business model whose objective is collecting contractual cash flows. The contractual cash flows of these financial assets represent solely payments of principal and interest that reflect consideration for the time value of money and the credit risk. Accordingly, these financial assets are measured at amortized cost. Cash includes cash balances available for immediate use. Deposits include short-term deposits with banking corporations (with original maturities of three months or more) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. (2) Non-derivative financial liabilities Non-derivative financial liabilities include trade and other payables. Initial recognition of financial liabilities The Group initially recognizes financial liabilities on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Transaction costs directly attributable to an expected issuance of an instrument that will be classified as a financial liability are recognized as an asset in the framework of deferred expenses in the statement of financial position. These transaction costs are deducted from the financial liability upon its initial recognition, or are amortized as financing expenses in the statement of profit or loss and other comprehensive income when the issuance is no longer expected to occur. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged or cancelled. Offset of financial instruments Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Measurement of derivative financial instruments Derivatives are recognized initially at fair value attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognized in profit or loss, as financing income or expense.
Property plant and equipment	F. Property plant and equipment Property plant and equipment are presented according to cost, including directly attributed acquisition costs, minus accumulated depreciation and losses from accrued decrease in value. Improvements and upgrades are included in the assets’ costs whereas maintenance and repair costs are recognized in profit and loss as accrued. Gains and losses on disposal of a fixed asset item are determined by comparing the net proceeds from disposal with the carrying amount of the asset, and are recognized in their corresponding section, in profit or loss. The cost of printers used for internal purposes, which are classified as property, plant and equipment, includes the cost of materials and direct labor, and any other costs directly attributable to bringing the assets to a working condition for their intended use. The depreciation is calculated in equal yearly rates during the period of the useful life span of the assets, as follows: % Machinery and equipment (mainly 7%) 7 – 25 Computers 20 – 33 Office furniture and equipment 7 – 15 Leasehold Improvements 7 – 10 Printers leased to customers 25 Depreciation methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate.
Inventory	G. Inventory Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the weighted averages method, and includes expenditure incurred in acquiring the inventories and the costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, cost includes an appropriate share of production overheads based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.
Impairment of non-financial assets	H. Impairment of non-financial assets The carrying amounts of the Group’s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. The recoverable amount of an asset is the greater of its value in use and its fair value, minus the costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the assessments of market participants regarding the time value of money and the risks specific to the asset, for which the estimated future cash flows from the asset were not adjusted. An impairment loss is recognized if the carrying amount of an asset exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.
Provisions	I. Provisions A provision for claims is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably and it is probable that an outflow of economic benefits will be required to settle the obligation. When the value of time is material, the provision is measured at its present value.
Treasury shares and Ordinary Shares	J. Treasury shares and Ordinary Shares When share capital recognized as equity is repurchased by the Group, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity, and the resulting surplus on the transaction is carried to share premium, whereas a deficit on the transaction is deducted from retained earnings. Ordinary Shares are classified as equity. Incremental costs directly attributable to the issuance of Ordinary Shares and share options are recognized as a deduction from equity, net of any tax effects.
Revenue recognition	K. Revenue recognition The Company recognizes revenue when the customer obtains control over the promised goods or services. The revenue is measured according to the amount of the consideration to which the Company expects to be entitled in exchange for the goods or services promised to the customer, other than amounts collected for third parties. The Company accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Company can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Company can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Company is entitled to in exchange for the goods or services transferred to the customer, will be collected. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Company has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. On the contract’s inception date, the Company assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer goods or services (or a bundle of goods or services) that are distinct. The Company identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Company’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. The Company’s identified performance obligations include: printer, ink, maintenance (which is generally provided for a period of up to one year), training and installation. Revenue is allocated among performance obligations in a manner that reflects the consideration that the Company expects to be entitled to for the promised goods based on the standalone selling prices (“SSP”) of the goods or services of each performance obligation. SSP are estimated for each distinct performance obligation and judgment may be required in their determination. The best evidence of SSP is the estimated price of a product or service if the Company would sell them separately in similar circumstances and to similar customers. The Company allocates the transaction price to the identified performance obligations based on the residual approach, while allocating the estimated standalone selling prices for performance obligations relating to maintenance, training and installation services, and the residual is allocated to the printer. Revenues allocated to the printers, installation and training, and ink and other consumables are recognized when the control is passed in accordance with the contract terms at a point in time. Maintenance revenue is recognized ratably, on a straight-line basis, over the period of the services. Revenue from training and installation is recognized during the time of performance. A contract asset is recognized when the Group has a right to consideration for goods or services it transferred to the customer that is conditional on other than the passing of time, such as future performance of the Group. Contract assets are classified as receivables when the rights in their respect become unconditional. A contract liability is recognized when the Group has an obligation to transfer goods or services to the customer for which it received consideration (or the consideration is payable) from the customer.
Research and development and intangible assets	L. Research and development and intangible assets Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use. In the fourth quarter of 2016, the Group ceased to capitalize development expenses and began to amortize the intangible asset arising from capitalization of development expenses, upon the initiation of its beta program. In subsequent periods, capitalized development expenditure is measured at cost minus accumulated amortization and accumulated impairment losses.
Amortization of intangible assets	M. Amortization of intangible assets Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset, minus its residual value. Amortization is recognized in profit or loss on a straight-line basis, over the estimated useful lives of the intangible assets from the date they are available for use, since these methods most closely reflect the expected pattern of consumption of the future economic benefits embodied in each asset. The estimated useful lives of the capitalized development costs have been determined by the Company’s management as 10 years. Amortization methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate.
Government grants	N. Government grants Government grants are recognized initially at fair value when there is reasonable assurance that they will be received and the Group will comply with the conditions associated with the grant. Grants from the Israeli Innovation Authority (the “Innovation Authority”), with respect to research and development projects, are accounted for as forgivable loans according to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. Grants received from the Innovation Authority are recognized as a liability according to their fair value on the date of their receipt, unless it is reasonably certain, on that date, that the amount received will not be refunded. The amount of the liability is reexamined each period, and any changes in the present value of the cash flows discounted at the original interest rate of the grant are recognized in profit or loss. The difference between the amount received and the fair value on the date of receiving the grant is recognized as a deduction of research and development expenses. Expenses related to revaluation of the liability in respect of government grants were recognized in the statements of profit or loss and other comprehensive income as finance expenses.
Leases	O. Leases Policy applicable before January 1, 2019 Determining whether an arrangement contains a lease At inception or upon reassessment of an arrangement, the Group determines whether such an arrangement is or contains a lease. An arrangement is a lease or contains a lease if the following two criteria are met: ● The fulfilment of the arrangement is dependent on the use of a specific asset or assets; and ● The arrangement contains rights to use the asset. Leases that do not transfer substantially all the risks and rewards incidental to ownership of an underlying asset were classified as operating leases. The Group recognized operating lease payments as expenses on a straight-line basis over the lease term. Policy applicable from January 1, 2019 Determining whether an arrangement contains a lease On the inception date of the lease, the Group determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, the Group assesses whether it has the following two rights throughout the lease term: (a) The right to obtain substantially all the economic benefits from use of the identified asset; and (b) The right to direct the identified asset’s use. For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, the Group elected to account for the contract as a single lease component without separating the components. Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-of-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group’s leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-of-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The Group has elected to apply the practical expedient by which short-term leases of up to one year and/or leases in which the underlying asset has a low value, are accounted for such that lease payments are recognized in profit or loss on a straight-line basis, over the lease term, without recognizing an asset and/or liability in the statement of financial position. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Variable lease payments Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-of-use asset. Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs. Depreciation of right-of-use asset After lease commencement, a right-of-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever is earlier, as follows: ● Buildings 1-5 years ● Motor vehicles 3 years Reassessment of lease liability Upon the occurrence of a significant event or a significant change in circumstances that is under the control of the Group and had an effect on the decision whether it is reasonably certain that the Group will exercise an option, which was not included before in the lease term, or will not exercise an option, which was previously included in the lease term, the Group re-measures the lease liability according to the revised leased payments using a new discount rate. The change in the carrying amount of the liability is recognized against the right-of-use asset, or recognized in profit or loss if the carrying amount of the right-of-use asset was reduced to zero. Lease modifications When a lease modification increases the scope of the lease by adding a right to use one or more underlying assets, and the consideration for the lease increased by an amount commensurate with the stand-alone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the contract’s circumstances, the Group accounts for the modification as a separate lease. In all other cases, on the initial date of the lease modification, the Group allocates the consideration in the modified contract to the contract components, determines the revised lease term and measures the lease liability by discounting the revised lease payments using a revised discount rate. For lease modifications that decrease the scope of the lease, the Group recognizes a decrease in the carrying amount of the right-of-use asset in order to reflect the partial or full cancellation of the lease, and recognizes in profit or loss a profit (or loss) that equals the difference between the decrease in the right-of-use asset and re-measurement of the lease liability. For other lease modifications, the Group re-measures the lease liability against the right-of-use asset.
Financing income and expenses	P. Financing income and expenses Financing income is comprised of interest income on deposits, revaluation of liability in respect of government grants, foreign currency gains and fair value changes of financial liabilities through profit and loss. Financing expenses are comprised of bank fees, exchange rate differences, revaluation of liability in respect of government grants and fair value changes of financial liabilities through profit and loss. Foreign currency gains and losses on financial assets and financial liabilities are reported on a net basis as either financing income or financing expenses depending on whether foreign currency movements are in a net gain or net loss position.
Employee benefits	Q. Employee benefits Severance pay The Group’s liability for severance pay for its employees is calculated pursuant to Israeli Severance Pay Law (1963) (the “Severance Pay Law”). The Group’s liability is covered by monthly deposits with severance pay funds and insurance policies. For all of the Group’s employees, the payments to pension funds and to insurance companies exempt the Group from any obligation towards its employees, in accordance with Section 14 of the Severance Pay Law, which is accounted for as a defined contribution plan (as defined below). Accumulated amounts in pension funds and in insurance companies are not under the Group’s control or management and, accordingly, neither those amounts nor the corresponding accrual for severance pay are presented in the consolidated statements of financial position. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Share-based payment arrangements in which the subsidiary grants rights to parent company equity instruments to its employees are accounted for by the Group as equity-settled share-based payment transactions.
Loss per share	R. Loss per share The Group presents basic and diluted loss per share for its Ordinary Shares. Basic loss per share is calculated by dividing the loss attributable to holders of Ordinary Shares of the Company by the weighted average number of Ordinary Shares outstanding during the year, adjusted for treasury shares. Diluted loss per share is determined by adjusting the loss attributable to holders of Ordinary Shares of the Company and the weighted average number of Ordinary Shares outstanding, after adjustment for treasury shares, for the effects of all dilutive potential Ordinary Shares.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Schedule of details regarding the exchange rate	Consumer Price Index Euro NIS December 31, 2020 101.1 1.22 0.31 December 31, 2019 101.8 1.12 0.29 December 31, 2018 101.2 1.14 0.27 Change in percentages: Year ended December 31, 2020 (0.69 ) (9.32 ) (2 ) Year ended December 31, 2019 0.6 (2 ) 8.45 ) Year ended December 31, 2018 0.8 (4.4 ) (7.5
Schedule of property plant and equipment, useful life span of the assets	% Machinery and equipment (mainly 7%) 7 – 25 Computers 20 – 33 Office furniture and equipment 7 – 15 Leasehold Improvements 7 – 10 Printers leased to customers 25

Cash and Restricted Deposits (T

Cash and Restricted Deposits (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Cash And Restricted Deposits Explanatory [Abstract]
Schedule of components of cash	December 31, 2019 2020 Thousands Thousands Bank accounts- dominated in NIS 348 1,057 Bank accounts- dominated in USD 3,536 584,205 Bank accounts- other 10 76 3,894 585,338

Trade Receivables and Other R_2

Trade Receivables and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2020
Trade and other receivables [Abstract]
Schedule of trade receivables	December 31, 2019 2020 Thousands Thousands Open balances 1,816 713
Schedule of other receivables	December 31, 2019 2020 Thousands Thousands Government authorities 332 400 Prepaid expenses 221 696 Others 17 30 570 1,126

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory [Abstract]
Schedule of inventory	December 31, 2019 2020 Thousands Thousands Raw materials and work in progress (*) 2,636 2,692 Finished goods 907 622 3,543 3,314 (*) A part of the raw materials and work in progress are expected to be sold in a period longer than the operating cycle of the Company.

Property Plant and Equipment,_2

Property Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property, plant and equipment [Abstract]
Schedule of property plant and equipment, net	Machinery and equipment Computers Office furniture and equipment Leasehold improvements Printers leased to clients Total Thousands Thousands Thousands Thousands Thousands Thousands Cost As of January 1, 2019 4,132 471 158 1,719 199 6,679 Additions 770 5 32 26 - 833 Disposals (306 ) - (3 ) - (87 ) (396 ) Designation change 112 - - - (112 ) - As of December 31, 2019 4,708 476 187 1,745 - 7,116 Additions 1,163 124 85 12 - 1,384 Disposals - (8 ) (22 ) - - (30 ) As of December 31, 2020 5,871 592 250 1,757 - 8,470 Depreciation accrued As of January 1, 2019 792 365 37 238 47 1,479 Disposals 799 65 17 166 13 1,060 Designation change (133 ) - (1 ) - (32 ) (166 ) Disposals 28 - - - (28 ) - As of December 31, 2019 1,486 430 53 404 - 2,373 Additions 787 47 30 167 - 1,031 Disposals - (8 ) (18 ) - - (26 ) As of December 31, 2020 2,273 469 65 571 - 3,378 Carrying amount As of December 31, 2020 3,598 123 185 1,186 - 5,092 As of December 31, 2019 3,222 46 134 1,341 - 4,743

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Intangible Assets [Abstract]
Schedule of intangible assets development expenses capitalized	2019 2020 Thousands Thousands Balance as of January 1 5,983 5,211 Amortization (772 ) (771 ) Balance as of December 31 5,211 4,440

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2020
Subsidiaries [Abstract]
Summary of group's material subsidiaries	Principal location The Group’s ownership interest in the subsidiary for the year ended December 31 2019 2020 Name of company % % Nano Dimension Technologies Ltd. Israel 100 % 100 % Nano Dimension IP Ltd. (*) Israel 100 % 100 % Nano Dimension USA Inc. USA 100 % 100 % Nano Dimension (HK) Limited (*) Asia-Pacific 100 % 100 % (*) Nano Dimension IP Ltd. and Nano Dimension (HK) Limited were incorporated by the Company in 2018. Nano Dimension IP Ltd. had no material activity until and during 2020.

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2020
Other Payables [Abstract]
Schedule of other payables	December 31, 2019 2020 Thousands Thousands Accrued expenses 406 1,635 Contract liabilities 991 968 Lease liability 1,055 1,148 Employees and related liabilities 616 1,230 Government authorities 249 659 Current maturities in respect of government grants 231 226 Others 27 44 3,575 5,910

Liability in Respect of Gover_2

Liability in Respect of Government Grants (Tables)	12 Months Ended
	Dec. 31, 2020
Liability in Respect of Government Grants [Abstract]
Schedule of liability in respect of government grants	2019 2020 Thousands Thousands Balance as of January 1 1,445 1,275 Amounts received during the year 121 55 Payment of royalties (185 ) (158 ) Amounts recognized as an offset from research and development expenses (49 ) (23 ) Revaluation of the liability (57 ) (73 ) Balance as of December 31 1,275 1,076 Current maturities in respect of government grants 231 226 Long term liability in respect of government grants 1,044 850

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Schedule of share capital	Ordinary Shares 2019(*) 2020 Issued and paid-up share capital as at December 31 4,179 172,052 Authorized share capital 10,000 250,000 (*) Following the approval of its shareholders on April 16, 2020, the board of directors of the Company approved a 1-for-50 reverse split of the Company’s share capital. The implementation of the reverse split resulted in a reduction in the issued and outstanding Ordinary Shares, and the increase of the par value per Ordinary Share from NIS 0.10 to NIS 5.00 per Ordinary Share. Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares to each of the Company’s ADSs, such that its ratio of ADSs to Ordinary Shares has changed from one (1) ADS representing fifty (50) Ordinary Shares to a new ratio of one (1) ADS representing one (1) Ordinary Share. The effective date of this reverse split was June 29, 2020. All options and warrants of the Company outstanding immediately prior to the reverse split were appropriately adjusted by dividing the number of Ordinary Shares into which the options and warrants are exercisable by 50 and multiplying the exercise price thereof by 50, as a result of the reverse split. All the figures in these financial statements relating to share capital were appropriately adjusted to reflect the above-mentioned reverse split.
Schedule of issued share capital	Ordinary Shares 2019 2020 Issued as at January 1 1,931 4,179 Issued for cash during the period 1,600 163,542 Conversion into shares of convertible notes during the period 610 1,395 Exercise of warrants during the period 38 2,918 Exercise of share options during the period - 18 Issued and paid-in share capital as at December 31 4,179 172,052

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2020
Revenues [Abstract]
Schedule of revenue	For the year ended 2018 2019 2020 Thousands Thousands Thousands Consumables 190 650 554 Support services 400 598 654 Sales of printers 4,320 5,770 2,191 Total 4,910 7,018 3,399 Printers rental 190 52 - Total revenue 5,100 7,070 3,399
Schedule of revenues per geographical locations	For the year ended 2018 2019 2020 Thousands Thousands Thousands U.S. 2,727 3,367 1,263 Asia Pacific 1,239 1,591 1,362 Europe and Israel(*) 1,134 2,112 774 Total revenue 5,100 7,070 3,399 (*) The Company combined all revenues into the Europe and Israel geography, due to immateriality of the amounts.
Schedule of timing of revenue recognition	For the year ended 2018 2019 2020 Thousands Thousands Thousands Goods and services transferred over time 590 650 654 Goods transferred at a point in time 4,510 6,420 2,745 Total revenue 5,100 7,070 3,399
Schedule of contract assets and contract liabilities deriving from contracts with customers	December 31, 2019 2020 Thousands Thousands Open balances 1,816 713 Contract liabilities 991 968

Cost of Revenues (Tables)

Cost of Revenues (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of cost of sales [text block] [Abstract]
Schedule of cost of revenues	For the year ended 2018 2019 2020 Thousands Thousands Thousands According to sources of revenue - Consumables 195 240 169 Support services 403 855 629 Sales of printers 2,938 3,192 765 Printers rental 58 25 - Total 3,594 4,312 1,563

Further Detail of Profit or L_2

Further Detail of Profit or Loss (Tables)	12 Months Ended
	Dec. 31, 2020
Profit or loss [abstract]
Schedule of further detail of profit or loss	For the year ended 2018 2019 2020 Thousands Thousands Thousands A. Research and development expenses, net Payroll 4,890 4,834 6,531 Materials 1,065 1,001 940 Subcontractors 70 82 258 Patent registration 70 144 160 Depreciation 880 1,534 1,588 Rental fees and maintenance 908 197 173 Other 782 339 249 8,665 8,131 9,899 Less – government grants (42 ) (49 ) (21 ) 8,623 8,082 9,878 B. Sales and marketing expenses Payroll 2,226 2,873 5,326 Marketing, advertising and commissions 1,381 1,808 577 Rental fees and maintenance 64 114 201 Travel abroad 201 317 235 Depreciation 186 212 223 Other 201 145 35 4,259 5,469 6,597 C. General and administrative expenses Payroll 819 (*) 872 (*) 1,377 Share based payment expenses 206 (*) 155 (*) 16,837 Fees 32 22 22 Professional services 1,114 1,358 1,064 Directors pay 209 (*) 187 (*) - Office expenses 311 359 386 Travel abroad 45 37 44 Depreciation - 78 76 Rental fees and maintenance 91 43 46 Other 107 159 435 3,002 3,270 20,287 D. Finance income Revaluation of liability in respect of government grants - 58 75 Exchange rate differences - - 123 Revaluation of financial liabilities at fair value through profit or loss (**) - 8,707 - Bank interest and fees 54 - 248 54 8,765 446 Finance expense Exchange rate differences 127 151 - Bank fees - 14 28 Finance expense in respect of lease liability - 425 390 Revaluation of financial liabilities at fair value through profit or loss (**) - - 12,825 Fundraising expenses - 1,693 - Revaluation of liability in respect of government grants 265 - - 392 2,283 13,243 (*) Reclassified. (**) See Note 11.B regarding financing transactions that included issuance of financial instruments accounted at fair value through profit and loss.

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax [Abstract]
Schedule of adjustment between the theoretical tax amount and the tax amount	For the year ended 2018 2019 2020 Thousands Thousands Thousands Total comprehensive loss (15,488 ) (8,353 ) (48,494 ) Statutory tax rate 23 % 23 % 23 % Theoretical tax benefit (3,562 ) (1,921 ) (11,154 ) Increase in tax liability due to: Non-deductible expenses 280 75 4,299 Losses and benefits for tax purposes for which no deferred taxes were recorded 3,282 1,846 6,855 Taxes on income - - -

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings per share [Abstract]
Schedule of loss per share	For the year ended 2018(*) 2019(*) 2020 Weighted average of number of Ordinary Shares used in the calculation of basic and diluted loss per share (in thousands)(*) 1,836 3,513 42,947 Net loss used in calculation (thousands USD) 15,488 8,353 48,494 (*) All the figures in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A.
Schedule of weighted average number of ordinary shares	Year ended 2018(*) 2019(*) 2020 Thousands Thousands Thousands shares of shares of shares of par value par value par value Balance as at January 1 1,240 1,932 4,179 Effect of share options exercised 1 135 9 Effect of warrants exercised - - 1,184 Effect of conversion of notes - - 1,236 Effect of shares issued during the year 595 1,446 36,339 Weighted average number of Ordinary Shares used to calculate basic and diluted earnings (loss) per share as at December 31 1,836 3,513 42,947 (*) All the figures in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A.

Share-Based Payment (Tables)

Share-Based Payment (Tables)	12 Months Ended
	Dec. 31, 2020
Share-Based Payment (Tables) [Line Items]
Schedule of fair value of the share options	17.A- 17.B- Number of share options granted 14,638,264 8,942,202 (*) Fair value in the grant date (thousands USD) 43,979 23,434 Range of share price (USD) 0.74-89.83 1.38-94.64 Range of exercise price (USD) 0-114.77 0.7-92.04 Range of expected share price volatility 40.3%-104.96 % 53.75-104.96 % Range of estimated life (years) 4-9 4-7 Range of weighted average of risk-free interest rate 0.36-1.98 % 0.88%-1.32 % Expected dividend yield - - Outstanding as of December 31, 2020 12,603,828 8,839,482 Exercisable as of December 31, 2020 880,734 8,679,113 (*) The options granted to directors and the CEO do not include the series B warrants which the CEO is entitled to purchase, since the number of those warrants is not yet determined.
Employees and consultants [Member]
Share-Based Payment (Tables) [Line Items]
Schedule of fair value of the share options	2019(*) 2020 Outstanding at January 1 112,944 521,138 Granted during the year 461,223 14,295,289 Exercised during the year (24 ) (1,703,902 ) Forfeited or expired during the year (53,005 ) (508,697 ) Outstanding at December 31 521,138 12,603,828 Exercisable as of December 31 53,831 880,734
Directors and CEO [Member]
Share-Based Payment (Tables) [Line Items]
Schedule of fair value of the share options	2019 2020 Outstanding at January 1 41,400 78,435 Granted during the year 50,900 8,820,402 Exercised during the year - - Forfeited or expired during the year (13,865 ) (59,355 ) Outstanding at December 31 78,435 8,839,482 Exercisable as of December 31 40,275 8,679,113

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Financial Instruments [Abstract]
Schedule of classification and linkage terms of financial instruments	NIS Linked to the U.S. dollar Linked to the Euro and other Total December 31, 2020 Cash 1,057 584,205 76 585,338 Bank deposits - 85,596 - 85,596 Restricted deposits 406 62 - 468 Trade receivables 17 534 162 713 Other receivables 410 19 - 429 1,890 670,416 238 672,544 Financial liabilities at amortized cost 4,366 16,134 45 20,545 Total net financial assets (liabilities) (2,476 ) 654,282 193 651,999 December 31, 2019 Cash 348 3,536 10 3,894 Restricted deposits 377 31 - 408 Trade receivables - 1,586 230 1,816 Other receivables 342 - - 342 1,067 5,153 240 6,460 Financial liabilities at amortized cost 4,503 6,740 13 11,256 Total net financial assets (liabilities) (3,436 ) (1,587 ) 227 (4,796 )
Schedule of sensitivity analysis of changes in exchange rate of dollar	Profit (loss) Thousands Increase at a rate of 5% (124 ) Increase at a rate of 10% (248 ) Decrease at a rate of 5% 124 Decrease at a rate of 10% 248
Schedule of fair value of financial instruments position	December 31, 2020 Level 1 Level 2 Level 3 Total Thousands Thousands Thousands Thousands Financial liabilities: Warrants - 11,636 - 11,636 Financial derivatives - 350 - 350 Total - 11,986 - 11,986 December 31, 2019 Level 1 Level 2 Level 3 Total Thousands Thousands Thousands Thousands Financial liabilities: Warrants - 793 1,364 2,157 Convertible notes - - 1,223 1,223 Financial derivatives - - 318 318 Total - 793 2,905 3,698
Schedule of repayment dates of financial liabilities	First year More than a year Total Thousands Thousands Thousands December 31, 2020 Trade payables 776 - 776 Other payables 5,910 - 5,910 Lease liabilities - 2,618 2,618 Liability in respect of government grants - 850 850 6,686 3,468 10,154 December 31, 2019 Trade payables 850 - 850 Other payables 3,547 28 3,575 Lease liabilities - 2,089 2,089 Liability in respect of government grants - 1,044 1,044 4,397 3,161 7,558

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of lease liability and right of use asset	Buildings Vehicles Total Thousands Thousands Thousands Balance as at January 1, 2019 1,687 204 1,891 Depreciation 706 136 842 Additions 1,525 99 1,624 Balance as at January 1, 2020 2,506 167 2,673 Depreciation 740 116 856 Disposals - 69 69 Additions 1,312 109 1,421 Balance as at December 31, 2020 3,078 91 3,169
Schedule of maturity analysis of the group's lease liabilities	December 31, Thousands Less than one year 1,148 One to five years 2,618 Total 3,766 Current maturities of lease liability 1,148 Long-term lease liability 2,618

Transactions and balances wit_2

Transactions and balances with related parties (Tables)	12 Months Ended
	Dec. 31, 2020
Transactions and balances with related parties [Abstract]
Schedule of Balances with related parties	December 31, 2019 2020 Thousands Thousands Other payables 130 207
Schedule of Shareholder and other related parties benefits	Year ended on December 31, 2018 2019 2020 Thousands Thousands Thousands Salaries and related expenses- related parties employed by the Group 829 1,047 18,252 (*) Number of related parties 4 4 5 Compensation for directors not employed by the Group 311 218 2,204 Number of directors 7 6 6

General (Details)

General (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
General Hedge Accounting [Abstract]
Aggregate gross proceeds	$ 710,000,000
Gross proceeds	$ 833,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives of the capitalized development costs	10 years
Buildings [member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives of the capitalized development costs	1 year
Buildings [member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives of the capitalized development costs	5 years
Motor vehicles [member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives of the capitalized development costs	3 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of details regarding the exchange rate	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of details regarding the exchange rate [Abstract]
Consumer Price Index	101.1	101.8	101.2
Exchange rate of Euro	1.22	1.12	1.14
Exchange rate of NIS	0.31	0.29	0.27
Change in percentages of consumer price index	(0.69%)	0.60%	0.80%
Change in percentages of Euro	(9.32)	(2)	(4.4)
Change in percentages of NIS	(2.00%)	8.45%	7.50%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets	12 Months Ended
	Dec. 31, 2020
Machinery and equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	7.00%
Machinery and equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	25.00%
Computers [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	20.00%
Computers [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	33.00%
Office furniture and equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	7.00%
Office furniture and equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	15.00%
Leasehold Improvements [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	7.00%
Leasehold Improvements [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	10.00%
Printers leased to customers [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment, useful life span of the assets [Line Items]
Depreciation rates useful life span of assets	25.00%

Cash and Restricted Deposits (D

Cash and Restricted Deposits (Details) - Lease [Member] $ in Thousands	Dec. 31, 2020USD ($)
Cash and Restricted Deposits (Details) [Line Items]
Restricted deposit	$ 468
Annual interest rate	0.01%

Cash and Restricted Deposits _2

Cash and Restricted Deposits (Details) - Schedule of components of cash - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Cash and Restricted Deposits (Details) - Schedule of components of cash [Line Items]
Bank accounts- other	$ 76	$ 10
Cash	585,338	3,894
NIS [Member]
Cash and Restricted Deposits (Details) - Schedule of components of cash [Line Items]
Bank accounts- dominated in NIS	1,057	348
USD [Member]
Cash and Restricted Deposits (Details) - Schedule of components of cash [Line Items]
Bank accounts- dominated in USD	$ 584,205	$ 3,536

Trade Receivables and Other R_3

Trade Receivables and Other Receivables (Details) - Schedule of trade receivables - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of trade receivables [Abstract]
Open balances	$ 713	$ 1,816

Trade Receivables and Other R_4

Trade Receivables and Other Receivables (Details) - Schedule of other receivables - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of other receivables [Abstract]
Government authorities	$ 400	$ 332
Prepaid expenses	696	221
Others	30	17
Total	$ 1,126	$ 570

Inventory (Details) - Schedule

Inventory (Details) - Schedule of inventory - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Schedule of inventory [Abstract]
Raw materials and work in progress	[1]	$ 2,692	$ 2,636
Finished goods		622	907
Total		$ 3,314	$ 3,543
[1]	A part of the raw materials and work in progress are expected to be sold in a period longer than the operating cycle of the Company.

Property Plant and Equipment,_3

Property Plant and Equipment, Net (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Disclosure of property, plant and equipment [text block] [Abstract]
Acquired property plant and equipment	$ 25,000

Property Plant and Equipment,_4

Property Plant and Equipment, Net (Details) - Schedule of property plant and equipment, net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cost
Beginning balance	$ 7,116	$ 6,679
Additions	1,384	833
Disposals	(30)	(396)
Designation change
Ending balance	8,470	7,116
Depreciation accrued
Beginning balance	2,373	1,479
Additions	1,031	1,060
Designation change		(166)
Disposals	(26)
Ending balance	3,378	2,373
Carrying amount
Property plant and equipment, net	5,092	4,743
Machinery and equipment [Member]
Cost
Beginning balance	4,708	4,132
Additions	1,163	770
Disposals		(306)
Designation change		112
Ending balance	5,871	4,708
Depreciation accrued
Beginning balance	1,486	792
Additions	787	799
Designation change		(133)
Disposals		28
Ending balance	2,273	1,486
Carrying amount
Property plant and equipment, net	3,598	3,222
Computers [Member]
Cost
Beginning balance	476	471
Additions	124	5
Disposals	(8)
Designation change
Ending balance	592	476
Depreciation accrued
Beginning balance	430	365
Additions	47	65
Designation change
Disposals	(8)
Ending balance	469	430
Carrying amount
Property plant and equipment, net	123	46
Office furniture and equipment [Member]
Cost
Beginning balance	187	158
Additions	85	32
Disposals	(22)	(3)
Designation change
Ending balance	250	187
Depreciation accrued
Beginning balance	53	37
Additions	30	17
Designation change		(1)
Disposals	(18)
Ending balance	65	53
Carrying amount
Property plant and equipment, net	185	134
Leasehold improvements [Member]
Cost
Beginning balance	1,745	1,719
Additions	12	26
Disposals
Designation change
Ending balance	1,757	1,745
Depreciation accrued
Beginning balance	404	238
Additions	167	166
Designation change
Disposals
Ending balance	571	404
Carrying amount
Property plant and equipment, net	1,186	1,341
Printers leased to clients [Member]
Cost
Beginning balance	0	199
Additions
Disposals		(87)
Designation change		(112)
Ending balance		0
Depreciation accrued
Beginning balance		47
Additions		13
Designation change		(32)
Disposals		(28)
Ending balance
Carrying amount
Property plant and equipment, net

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets development expenses capitalized - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of intangible assets development expenses capitalized [Abstract]
Balance as of January 1	$ 5,211	$ 5,983
Amortization	(771)	(772)
Balance as of December 31	$ 4,440	$ 5,211

Subsidiaries (Details) - Schedu

Subsidiaries (Details) - Schedule of group's material subsidiaries		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Nano Dimension Technologies Ltd. [Member]
Subsidiaries (Details) - Schedule of group's material subsidiaries [Line Items]
Name of company		Nano Dimension Technologies Ltd.
Principal location of the company's activity		Israel
The Group's ownership interest in the subsidiary		100.00%	100.00%
Nano Dimension IP Ltd. [Member]
Subsidiaries (Details) - Schedule of group's material subsidiaries [Line Items]
Name of company	[1]	Nano Dimension IP Ltd. (*)
Principal location of the company's activity	[1]	Israel
The Group's ownership interest in the subsidiary	[1]	100.00%	100.00%
Nano Dimension USA Inc. [Member]
Subsidiaries (Details) - Schedule of group's material subsidiaries [Line Items]
Name of company		Nano Dimension USA Inc.
Principal location of the company's activity		USA
The Group's ownership interest in the subsidiary		100.00%	100.00%
Nano Dimension (HK) Limited [Member]
Subsidiaries (Details) - Schedule of group's material subsidiaries [Line Items]
Name of company	[1]	Nano Dimension (HK) Limited (*)
Principal location of the company's activity	[1]	Asia-Pacific
The Group's ownership interest in the subsidiary	[1]	100.00%	100.00%
[1]	Nano Dimension IP Ltd. and Nano Dimension (HK) Limited were incorporated by the Company in 2018. Nano Dimension IP Ltd. had no material activity until and during 2020.

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of other payables - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of other payables [Abstract]
Accrued expenses	$ 1,635	$ 406
Contract liabilities	968	991
Lease liability	1,148	1,055
Employees and related liabilities	1,230	616
Government authorities	659	249
Current maturities in respect of government grants	226	231
Others	44	27
Other payables, Total	$ 5,910	$ 3,575

Liability in Respect of Gover_3

Liability in Respect of Government Grants (Details) - USD ($)	12 Months Ended	72 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Liability in Respect of Government Grants (Details) [Line Items]
Total approved budget for development project (in Dollars)		$ 4,505,000
Aggregate amount (in Dollars)	$ 1,865,000
Bottom of range [member]
Liability in Respect of Government Grants (Details) [Line Items]
Percentage of financing from the government		30.00%
Royalties		3.00%
Discount rate		19.00%
Top of range [member]
Liability in Respect of Government Grants (Details) [Line Items]
Percentage of financing from the government		50.00%
Royalties		3.50%
Discount rate		30.00%

Liability in Respect of Gover_4

Liability in Respect of Government Grants (Details) - Schedule of liability in respect of government grants - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of liability in respect of government grants [Abstract]
Balance as of January 1	$ 1,275	$ 1,445
Amounts received during the year	55	121
Payment of royalties	(158)	(185)
Amounts recognized as an offset from research and development expenses	(23)	(49)
Revaluation of the liability	(73)	(57)
Balance as of December 31	1,076	1,275
Current maturities in respect of government grants	226	231
Long term liability in respect of government grants	$ 850	$ 1,044

Equity (Details)

Equity (Details)	1 Months Ended				3 Months Ended	12 Months Ended
	Apr. 16, 2020$ / shares	Aug. 31, 2019USD ($)	Feb. 28, 2019USD ($)$ / sharesshares	Feb. 28, 2019XUAshares	Mar. 31, 2019USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	Feb. 28, 2021ILS (₪)shares	Jan. 31, 2021shares	Jun. 30, 2020shares	Feb. 04, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)shares
Equity (Details) [Line Items]
Ordinary shares issued (in Shares) | shares						4,179	74,100,000	74,100,000			1,931
Non-tradable rights term			6 months	6 months
Gross proceeds from offering						$ 833,000,000
Remaining financial liabilities						10,892,000
Financial liability						$ 10,154,000					$ 7,558,000
Treasury Shares [Member]
Equity (Details) [Line Items]
Ordinary shares issued (in Shares) | shares						10,540
Constituted issued and paid up share capital percentage						0.006%
Warrants [Member]
Equity (Details) [Line Items]
Remaining financial liabilities						$ 745,000
General Meeting [Member]
Equity (Details) [Line Items]
Ordinary shares issued (in Shares) | shares							500,000,000		250,000,000
Increased its authorized share capital (in New Shekels) | ₪							₪ 1,250,000,000
Ordinary shares [member]
Equity (Details) [Line Items]
Gross proceeds from offering			$ 10,560,000
Right to purchase exercised ordinary shares (in Shares) | shares					37,620
Bottom of range [member]
Equity (Details) [Line Items]
Par value per Ssare (in Dollars per share) | $ / shares	$ 0.10
Top of range [member]
Equity (Details) [Line Items]
Par value per Ssare (in Dollars per share) | $ / shares	$ 5
Investor [Member] | Ordinary shares [member]
Equity (Details) [Line Items]
Consideration received, net					$ 282,000
Right to purchase exercised ordinary shares (in Shares) | shares					37,620
Convertible notes [Member]
Equity (Details) [Line Items]
Consideration received, net						4,276,000
Financial liability						11,609,000
Convertible notes						$ 7,333,000
Loss on conversion price											$ 2,003,000
Non-adjusting events after reporting period [member] | Convertible notes [Member]
Equity (Details) [Line Items]
Aggregate principal amount										$ 204,000
Non-adjusting events after reporting period [member] | Convertible notes [Member] | ADS [Member]
Equity (Details) [Line Items]
Aggregate principal amount										$ 2,305,000
Conversion price (in Dollars per share) | $ / shares										$ 1.74
Non-adjusting events after reporting period [member] | Convertible notes [Member] | Warrants [Member] | ADS [Member]
Equity (Details) [Line Items]
Exercise price (in Dollars per share) | $ / shares										$ 1.914
Public Offering [Member] | Ordinary shares [member]
Equity (Details) [Line Items]
Consideration received, net | XUA				XUA 12,000,000
Attributed to warrants			10,201,000
Gross proceeds from offering			1,440,000
Net issuance consideration, total			1,224,000
Warrants description						the Company issued, pursuant to several public offerings in the United States, an aggregate of 163,542,447 ADSs and 430,000 pre-funded warrants (that were converted to ADSs during 2020). The total gross proceeds from the offerings were approximately $710,013,000, before deducting underwriting discounts and commissions and other offering-related expenses. The total net proceeds from the offerings, after deducting issuance expenses, were approximately $650,115,000. As a part of those offerings, the Company issued a total of 7,365,289 non-tradable warrants to the underwriters. The warrants are accounted for as share-based payment expenses, see also note 17.
Public Offering [Member] | Ordinary shares [member] | ADS [Member]
Equity (Details) [Line Items]
Attributed to warrants			1,799,000
Net issuance consideration, total			$ 216,000
Private Placement [Member]
Equity (Details) [Line Items]
Securities purchase agreement, description						Accordingly, from the consideration received, approximately $1,569,000 was attributed to the convertible notes of the first tranche, $1,902,000 was attributed to the warrants of the first tranche, and a total of approximately $805,000 was attributed to the rights with respect to the second and third tranches.
Ordinary shares issued (in Shares) | shares											609,448
Aggregate principal amount		$ 4,276,000									$ 1,767,400
Additional debt amount		2,700,000
Gross proceeds		$ 7,000,000
Non tradable warrants to purchase description		the Company issued non-tradable warrants to purchase 62,668,850 ADSs. The warrants have an exercise price equal to 125% of the conversion price of the convertible promissory notes, will be exercisable upon the six-month anniversary of issuance and will expire five years from the date of issuance. The total gross proceeds from the first closing were $4,276,000.
Conversion price (in Dollars per share) | $ / shares						$ 2.90
ADS [Member]
Equity (Details) [Line Items]
Securities purchase agreement, description	the Company effected a corresponding change in the ratio of ordinary shares to each of the Company’s ADSs, such that its ratio of ADSs to Ordinary Shares has changed from one (1) ADS representing fifty (50) Ordinary Shares to a new ratio of one (1) ADS representing one (1) Ordinary Share. The effective date of this reverse split was June 29, 2020. All options and warrants of the Company outstanding immediately prior to the reverse split were appropriately adjusted by dividing the number of Ordinary Shares into which the options and warrants are exercisable by 50 and multiplying the exercise price thereof by 50, as a result of the reverse split. All the figures in these financial statements relating to share capital were appropriately adjusted to reflect the above-mentioned reverse split.
Number of american depositary share (in Shares) | shares			1,600,000	1,600,000
Number of non-tradable warrants (in Shares) | shares			1,600,000	1,600,000
Non-tradable warrants exercise price (in Dollars per share) | $ / shares			$ 8.625
Non-tradable warrants term			5 years	5 years
Non-tradable rights to purchase shares (in Shares) | shares			1,200,000	1,200,000
Non-tradable rights exercise price (in Dollars per share) | $ / shares			$ 7.50

Equity (Details) - Schedule of

Equity (Details) - Schedule of share capital - shares	Dec. 31, 2020	Dec. 31, 2019	[1]
Schedule of share capital [Abstract]
Issued and paid-up share capital as at December 31	172,052	4,179
Authorized share capital	250,000	10,000
[1]	Following the approval of its shareholders on April 16, 2020, the Board of Directors of the Company approved a 1-for-50 reverse split of the Company’s share capital. The implementation of the reverse split resulted in a reduction in the issued and outstanding ordinary shares, and the increase of the par value per ordinary share from NIS 0.10 to NIS 5.00 per ordinary share. Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares to each of the Company’s ADSs, such that its ratio of ADSs to ordinary shares has changed from one (1) ADS representing fifty (50) ordinary shares to a new ratio of one (1) ADS representing one (1) ordinary share. The effective date of this reverse split was June 29, 2020. All options and warrants of the Company outstanding immediately prior to the reverse split were appropriately adjusted by dividing the number of ordinary shares into which the options and warrants are exercisable by 50 and multiplying the exercise price thereof by 50, as a result of the reverse split. All the figures in these financial statements relating to share capital were appropriately adjusted to reflect the above-mentioned reverse split.

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of issued share capital - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019		Feb. 28, 2021	Jan. 31, 2021
Schedule of issued share capital [Abstract]
Issued as at January 1	4,179	1,931		74,100,000	74,100,000
Issued for cash during the period	163,542	1,600
Conversion into shares of convertible notes during the period	1,395	610
Exercise of warrants during the period	2,918	38
Exercise of share options during the period	18
Issued and paid-in share capital as at December 31	172,052	4,179	[1]
[1]	Following the approval of its shareholders on April 16, 2020, the Board of Directors of the Company approved a 1-for-50 reverse split of the Company’s share capital. The implementation of the reverse split resulted in a reduction in the issued and outstanding ordinary shares, and the increase of the par value per ordinary share from NIS 0.10 to NIS 5.00 per ordinary share. Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares to each of the Company’s ADSs, such that its ratio of ADSs to ordinary shares has changed from one (1) ADS representing fifty (50) ordinary shares to a new ratio of one (1) ADS representing one (1) ordinary share. The effective date of this reverse split was June 29, 2020. All options and warrants of the Company outstanding immediately prior to the reverse split were appropriately adjusted by dividing the number of ordinary shares into which the options and warrants are exercisable by 50 and multiplying the exercise price thereof by 50, as a result of the reverse split. All the figures in these financial statements relating to share capital were appropriately adjusted to reflect the above-mentioned reverse split.

Revenues (Details) - Schedule o

Revenues (Details) - Schedule of revenue - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues (Details) - Schedule of revenue [Line Items]
Total	$ 3,399	$ 7,018	$ 4,910
Printers rental		52	190
Total revenue	3,399	7,070	5,100
Consumables [Member]
Revenues (Details) - Schedule of revenue [Line Items]
Total	554	650	190
Support services [Member]
Revenues (Details) - Schedule of revenue [Line Items]
Total	654	598	400
Sales of printers [Member]
Revenues (Details) - Schedule of revenue [Line Items]
Total	$ 2,191	$ 5,770	$ 4,320

Revenues (Details) - Schedule_2

Revenues (Details) - Schedule of revenues per geographical locations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues (Details) - Schedule of revenues per geographical locations [Line Items]
Total revenue		$ 3,399	$ 7,070	$ 5,100
U.S. [Member]
Revenues (Details) - Schedule of revenues per geographical locations [Line Items]
Total revenue		1,263	3,367	2,727
Asia Pacific [Member]
Revenues (Details) - Schedule of revenues per geographical locations [Line Items]
Total revenue		1,362	1,591	1,239
Europe and Israel [Member]
Revenues (Details) - Schedule of revenues per geographical locations [Line Items]
Total revenue	[1]	$ 774	$ 2,112	$ 1,134
[1]	The Company combined all revenues into the Europe and Israel geography, due to immateriality of the amounts.

Revenues (Details) - Schedule_3

Revenues (Details) - Schedule of timing of revenue recognition - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues (Details) - Schedule of timing of revenue recognition [Line Items]
Total revenue	$ 3,399	$ 7,070	$ 5,100
Goods and services transferred over time [Member]
Revenues (Details) - Schedule of timing of revenue recognition [Line Items]
Total revenue	654	650	590
Goods transferred at a point in time [Member]
Revenues (Details) - Schedule of timing of revenue recognition [Line Items]
Total revenue	$ 2,745	$ 6,420	$ 4,510

Revenues (Details) - Schedule_4

Revenues (Details) - Schedule of contract assets and contract liabilities deriving from contracts with customers - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of contract assets and contract liabilities deriving from contracts with customers [Abstract]
Open balances	$ 713	$ 1,816
Contract liabilities	$ 968	$ 991

Cost of Revenues (Details) - Sc

Cost of Revenues (Details) - Schedule of cost of revenues - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
According to sources of revenue -
Cost of revenues	$ 1,563	$ 4,312	$ 3,594
Consumables [Member]
According to sources of revenue -
Cost of revenues	169	240	195
Support services [Member]
According to sources of revenue -
Cost of revenues	629	855	403
Sales of printers [Member]
According to sources of revenue -
Cost of revenues	765	3,192	2,938
Printers rental [Member]
According to sources of revenue -
Cost of revenues		$ 25	$ 58

Further Detail of Profit or L_3

Further Detail of Profit or Loss (Details) - Schedule of further detail of profit or loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019		Dec. 31, 2018
A. Research and development expenses, net
Payroll		$ 6,531	$ 4,834		$ 4,890
Materials		940	1,001		1,065
Subcontractors		258	82		70
Patent registration		160	144		70
Depreciation		1,588	1,534		880
Rental fees and maintenance		173	197		908
Other		249	339		782
Research and development expenses, gross		9,899	8,131		8,665
Less – government grants		(21)	(49)		(42)
Research and development expenses, net		9,878	8,082		8,623
B. Sales and marketing expenses
Payroll		5,326	2,873		2,226
Marketing, advertising and commissions		577	1,808		1,381
Rental fees and maintenance		201	114		64
Travel abroad		235	317		201
Depreciation		223	212		186
Other		35	145		201
Sales and marketing expenses		6,597	5,469		4,259
C. General and administrative expenses
Payroll		1,377	872	[1]	819	[1]
Share based payment expenses		16,837	155	[1]	206	[1]
Fees		22	22		32
Professional services		1,064	1,358		1,114
Directors pay			187	[1]	209	[1]
Office expenses		386	359		311
Travel abroad		44	37		45
Depreciation		76	78
Rental fees and maintenance		46	43		91
Other		435	159		107
General and administrative expenses		20,287	3,270		3,002
D. Finance income
Revaluation of liability in respect of government grants		75	58
Exchange rate differences		123
Revaluation of financial liabilities at fair value through profit or loss	[2]		8,707
Bank interest and fees		248			54
Finance income		446	8,765		54
Exchange rate differences			151		127
Bank fees		28	14
Finance expense in respect of lease liability		390	425
Revaluation of financial liabilities at fair value through profit or loss	[2]	12,825
Fundraising expenses			1,693
Revaluation of liability in respect of government grants					265
Finance expense		$ 13,243	$ 2,283		$ 392
[1]	Reclassified.
[2]	See Note 11.B regarding financing transactions that included issuance of financial instruments accounted at fair value through profit and loss.

Income Tax (Details)

Income Tax (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 22, 2016	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of income tax [text block] [Abstract]
Percentage of corporate tax rates		23.00%	23.00%	23.00%
Description of corporate tax rate reduced	the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, the corporate tax rate would be reduced from 25% to 23% in two steps. The first step will be to a rate of 24% as from January 2017 and the second step will be to a rate of 23% as from January 2018.
Number of equal annual portion of amortization		3
Net operating loss for tax (in Dollars)		$ 79,688,000
Accumulated losses before the merger (in Dollars)		840,000
Tax deductible temporary difference value (in Dollars)		$ 31,634,000
Research and development deductible term period		3 years

Income Tax (Details) - Schedule

Income Tax (Details) - Schedule of adjustment between the theoretical tax amount and the tax amount - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of adjustment between the theoretical tax amount and the tax amount [Abstract]
Total comprehensive loss	$ (48,494)	$ (8,353)	$ (15,488)
Statutory tax rate	23.00%	23.00%	23.00%
Theoretical tax benefit	$ (11,154)	$ (1,921)	$ (3,562)
Increase in tax liability due to:
Non-deductible expenses	4,299	75	280
Losses and benefits for tax purposes for which no deferred taxes were recorded	6,855	1,846	3,282
Taxes on income

Loss Per Share (Details)

Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of earnings per share [text block] [Abstract]
Diluted weighted average number of ordinary shares	22,810,291	3,468,948	170,341
Reverse split, description	All the figures in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A.

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of loss per share - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	[1]	Dec. 31, 2018	[1]
Schedule of loss per share [Abstract]
Weighted average of number of Ordinary Shares used in the calculation of basic and diluted loss per share (in thousands)	42,947	3,513		1,836
Net loss used in calculation (thousands USD)	$ 48,494	$ 8,353		$ 15,488
[1]	All the figures in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A.

Loss Per Share (Details) - Sc_2

Loss Per Share (Details) - Schedule of weighted average number of ordinary shares - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	[1]	Dec. 31, 2018	[1]
Schedule of weighted average number of ordinary shares [Abstract]
Balance as at January 1	4,179	1,932		1,240
Effect of share options exercised	9	135		1
Effect of warrants exercised	1,184
Effect of conversion of notes	1,236
Effect of shares issued during the year	36,339	1,446		595
Weighted average number of Ordinary Shares used to calculate basic and diluted earnings (loss) per share as at December 31	42,947	3,513		1,836
[1]	All the figures in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A.

Share-Based Payment (Details)

Share-Based Payment (Details) - USD ($)	1 Months Ended							12 Months Ended
	Sep. 30, 2020	Aug. 31, 2020	Jul. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Jul. 31, 2019	Jan. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-Based Payment (Details) [Line Items]
Number of vested share options, description								the Company granted to employees 1,530,000 RSUs. The RSUs represents the right to receive Ordinary Shares at a future time and vest over a period of three years.	During 2019, the Company granted to employees 2,723,500 restricted shares units (“RSUs”). The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period of three years.
Borrowings, maturity				3 years
Fair value of grant of share based payment (in Dollars)		$ 18,700,000
Percentage of warrants exercised		30.00%
Consideration for warrants (in Dollars)					$ 2,157,000			$ 11,636,000	$ 2,157,000
Share based payment expenses (in Dollars)								20,502,000	$ 445,000
Deduction from share premium (in Dollars)								$ 25,718,000
Employees consultant and officers [Member]
Share-Based Payment (Details) [Line Items]
Number of granted non - tradable share options									6,029,000	2,652,500
Share options exercisable into ordinary shares									6,029,000	2,652,500
Number of vested share options, description								The share options vest over a period of three years.		The share options vest over a period of one to three years.
Employees consultant and officers [Member] | Bottom of range [member]
Share-Based Payment (Details) [Line Items]
Exercise price per share (in Dollars per share)								$ 0.70	$ 0.14	$ 0.28
Employees consultant and officers [Member] | Top of range [member]
Share-Based Payment (Details) [Line Items]
Exercise price per share (in Dollars per share)								$ 4.12	0.17	$ 1.59
Directors [Member]
Share-Based Payment (Details) [Line Items]
Number of granted non - tradable share options			440,000			2,545,000	300,000	5,400,000
Share options exercisable into ordinary shares			0.70				1.59	5,400,000
Number of vested share options, description			One third of the share options will vest after one year from the grant date, and the remaining will vest in eight equal quarterly batches over a period of two years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date.			One third of the share options will vest after one year from the grant date, and the remaining will vest in eight equal quarterly batches over a period of two years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date.
Exercise price per share (in Dollars per share)						$ 0.15
Number of vested share options, description							The share options will vest in 12 equal quarterly batches over a period of three years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date. 275,000 of the share options include a cashless exercise mechanism. In July 2019, the Company issued non-tradable share options to purchase 2,545,000 Ordinary Shares to directors of the Company at an exercise price of $0.15 per share. One third of the share options will vest after one year from the grant date, and the remaining will vest in eight equal quarterly batches over a period of two years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date.
Directors [Member] | ADSs [Member]
Share-Based Payment (Details) [Line Items]
Warrants granted	1,500,000
Warrants exercisable term	The warrants have an exercise price of $2.25 per ADS, will vest over a period of three years and will expire after 7 years.
Warrants exercise price (in Dollars per share)	$ 2.25
Underwriters [Member]
Share-Based Payment (Details) [Line Items]
Warrants granted								7,365,289
Number of ordinary shares exercisable by warrants								7,365,289
Warrants exercisable term								The warrants are exercisable 6 months from the issuance date, and expire 5 years after the issuance date.
Underwriters [Member] | Bottom of range [member]
Share-Based Payment (Details) [Line Items]
Exercise price per share (in Dollars per share)								$ 0.875
Underwriters [Member] | Top of range [member]
Share-Based Payment (Details) [Line Items]
Exercise price per share (in Dollars per share)								$ 9.375
Yoav Stern [Member]
Share-Based Payment (Details) [Line Items]
(in Dollars)		$ 150,000
Yoav Stern [Member] | ADSs [Member]
Share-Based Payment (Details) [Line Items]
Number of vested share options, description					The vesting start date of the share options is January 2, 2020.
Number of ADS purchase by issuances of option.				294,828	286,172
Exercise price per option (in Dollars per share)				$ 1.09	$ 2.86				$ 2.86
Percentage of option vested at the grant date				99.90%
Option vested term, description				the remaining options will vest 3 years after the grant date.
Number of ADS purchase by issuances of warrants		6,880,402
Warrants vesting term		The warrants have an exercise price of $0.75 per ADS, will vest over a period of two and a half years and will expire after 7 years.
Warrants exercise price (in Dollars per share)		$ 0.75
Number of additional american depository shares purchase by issuances of warrants		581,000
Warrants investing condition, description		In addition, as long as Mr. Stern is employed by the Company or is a member of the Company’s board of directors, Mr. Stern may invest an additional amount up to $50,000 to buy Series B Warrants, in an amount equal to 10% of the Company’s fully diluted capital.
Mr. Yaron Eitan [Member]
Share-Based Payment (Details) [Line Items]
Consideration for warrants (in Dollars)	$ 150,000

Share-Based Payment (Details) -

Share-Based Payment (Details) - Schedule of fair value of the share options $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Number of share options granted | shares
Consultants and Employees [Member]
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Number of share options granted | shares	14,638,264
Fair value in the grant date (thousands USD) | $	$ 43,979
Expected dividend yield | $
Outstanding as of December 31, 2020 | shares	12,603,828
Exercisable as of December 31, 2020 | shares	880,734
Consultants and Employees [Member] | Bottom of range [member]
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Range of share price (USD)	$ 0.74
Range of exercise price (USD)	$ 0
Range of expected share price volatility	40.30%
Range of estimated life (years)	4 years
Range of weighted average of risk-free interest rate	0.36%
Consultants and Employees [Member] | Top of range [member]
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Range of share price (USD)	$ 89.83
Range of exercise price (USD)	$ 114.77
Range of expected share price volatility	104.96%
Range of estimated life (years)	9 years
Range of weighted average of risk-free interest rate	1.98%
Directors and CEO [Member]
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Number of share options granted | shares	8,942,202
Fair value in the grant date (thousands USD) | $	$ 23,434
Expected dividend yield | $
Outstanding as of December 31, 2020 | shares	8,839,482
Exercisable as of December 31, 2020 | shares	8,679,113
Directors and CEO [Member] | Bottom of range [member]
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Range of share price (USD)	$ 1.38
Range of exercise price (USD)	$ 0.7
Range of expected share price volatility	53.75%
Range of estimated life (years)	4 years
Range of weighted average of risk-free interest rate	0.88%
Directors and CEO [Member] | Top of range [member]
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Range of share price (USD)	$ 94.64
Range of exercise price (USD)	$ 92.04
Range of expected share price volatility	104.96%
Range of estimated life (years)	7 years
Range of weighted average of risk-free interest rate	1.32%

Share-Based Payment (Details)_2

Share-Based Payment (Details) - Schedule of fair value of the share options and RSUs - Employees and consultants [Member] - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-Based Payment (Details) - Schedule of fair value of the share options and RSUs [Line Items]
Outstanding at January 1	521,138	112,944
Granted during the year	14,295,289	461,223
Exercised during the year	(1,703,902)	(24)
Forfeited or expired during the year	(508,697)	(53,005)
Outstanding at December 31	12,603,828	521,138
Exercisable as of December 31	880,734	53,831

Share-Based Payment (Details)_3

Share-Based Payment (Details) - Schedule of fair value of the share options - Directors and CEO [Member] - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-Based Payment (Details) - Schedule of fair value of the share options [Line Items]
Outstanding at January 1	78,435	41,400
Granted during the year	8,820,402	50,900
Exercised during the year
Forfeited or expired during the year	(59,355)	(13,865)
Outstanding at December 31	8,839,482	78,435
Exercisable as of December 31	8,679,113	40,275

Financial Instruments (Details)

Financial Instruments (Details) - Level 2 of fair value hierarchy [member]	12 Months Ended
	Dec. 31, 2020
Financial Instruments (Details) [Line Items]
Expected dividend yield	0.00%
Bottom of range [member]
Financial Instruments (Details) [Line Items]
Expected term of warrant	3 years 36 days
Expected volatility	118.77%
Risk-free rate	0.17%
Top of range [member]
Financial Instruments (Details) [Line Items]
Expected term of warrant	3 years 248 days
Expected volatility	128.10%
Risk-free rate	0.24%

Financial Instruments (Detail_2

Financial Instruments (Details) - Schedule of classification and linkage terms of financial instruments ₪ in Thousands, $ in Thousands	Dec. 31, 2020USD ($)	Dec. 31, 2020ILS (₪)	Dec. 31, 2019USD ($)	Dec. 31, 2019ILS (₪)
Financial Instruments (Details) - Schedule of classification and linkage terms of financial instruments [Line Items]
Cash	$ 585,338		$ 3,894
Bank deposits	85,596
Restricted deposits	468		408
Trade receivables	713		1,816
Other receivables	429		342
Financial assets	672,544		6,460
Financial liabilities at amortized cost	20,545		11,256
Total net financial assets (liabilities)	651,999		(4,796)
NIS [Member]
Financial Instruments (Details) - Schedule of classification and linkage terms of financial instruments [Line Items]
Cash | ₪		₪ 1,057		₪ 348
Bank deposits | ₪
Restricted deposits | ₪		406		377
Trade receivables | ₪		17
Other receivables | ₪		410		342
Financial assets | ₪		1,890		1,067
Financial liabilities at amortized cost | ₪		4,366		4,503
Total net financial assets (liabilities) | ₪		₪ (2,476)		₪ (3,436)
Linked to the U.S. dollar [Member]
Financial Instruments (Details) - Schedule of classification and linkage terms of financial instruments [Line Items]
Cash	584,205		3,536
Bank deposits	85,596
Restricted deposits	62		31
Trade receivables	534		1,586
Other receivables	19
Financial assets	670,416		5,153
Financial liabilities at amortized cost	16,134		6,740
Total net financial assets (liabilities)	654,282		(1,587)
Linked to the EURO and Other [Member]
Financial Instruments (Details) - Schedule of classification and linkage terms of financial instruments [Line Items]
Cash	76		10
Bank deposits
Restricted deposits
Trade receivables	162		230
Other receivables
Financial assets	238		240
Financial liabilities at amortized cost	45		13
Total net financial assets (liabilities)	$ 193		$ 227

Financial Instruments (Detail_3

Financial Instruments (Details) - Schedule of sensitivity analysis of changes in exchange rate of dollar $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Increase at a rate of 5% [Member]
Financial Instruments (Details) - Schedule of sensitivity analysis of changes in exchange rate of dollar [Line Items]
Changes in exchange rate	$ (124)
Increase at a rate of 10% [Member]
Financial Instruments (Details) - Schedule of sensitivity analysis of changes in exchange rate of dollar [Line Items]
Changes in exchange rate	(248)
Decrease at a rate of 5% [Member]
Financial Instruments (Details) - Schedule of sensitivity analysis of changes in exchange rate of dollar [Line Items]
Changes in exchange rate	124
Decrease at a rate of 10% [Member]
Financial Instruments (Details) - Schedule of sensitivity analysis of changes in exchange rate of dollar [Line Items]
Changes in exchange rate	$ 248

Financial Instruments (Detail_4

Financial Instruments (Details) - Schedule of fair value of financial instruments position - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Financial Instruments (Details) - Schedule of fair value of financial instruments position [Line Items]
Warrants	$ 11,636	$ 2,157
Convertible notes		1,223
Financial derivatives	350	318
Total	11,986	3,698
Level 1 [Member]
Financial Instruments (Details) - Schedule of fair value of financial instruments position [Line Items]
Warrants
Convertible notes
Financial derivatives
Total
Level 2 [Member]
Financial Instruments (Details) - Schedule of fair value of financial instruments position [Line Items]
Warrants	11,636	793
Convertible notes
Financial derivatives	350
Total	11,986	793
Level 3 [Member]
Financial Instruments (Details) - Schedule of fair value of financial instruments position [Line Items]
Warrants		1,364
Convertible notes		1,223
Financial derivatives		318
Total		$ 2,905

Financial Instruments (Detail_5

Financial Instruments (Details) - Schedule of repayment dates of financial liabilities - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Financial Instruments (Details) - Schedule of repayment dates of financial liabilities [Line Items]
Trade payables	$ 776	$ 850
Other payables	5,910	3,575
Lease liabilities	2,618	2,089
Liability in respect of government grants	850	1,044
Financial liabilities	10,154	7,558
First year [Member]
Financial Instruments (Details) - Schedule of repayment dates of financial liabilities [Line Items]
Trade payables	776	850
Other payables	5,910	3,547
Lease liabilities
Liability in respect of government grants
Financial liabilities	6,686	4,397
More than a year [Member]
Financial Instruments (Details) - Schedule of repayment dates of financial liabilities [Line Items]
Trade payables
Other payables		28
Lease liabilities	2,618	2,089
Liability in respect of government grants	850	1,044
Financial liabilities	$ 3,468	$ 3,161

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Leases (Details) [Line Items]
Lease liability	$ 2,618,000	$ 2,089,000
Lease liability and right-of-use asset	$ 3,169,000	2,673,000
Description of aforesaid lease agreements ends	The Group leases offices in Ness- Ziona from Africa-Israel for a period of five years under a few different contracts for three different floors used for offices, labs and manufacturing facilities, at the same building. The contractual periods of the aforesaid lease agreements end in August 2021, August 2024 and December 2023. The Group has an option to extend two of the lease agreements for an additional five years for an additional monthly fee (10% increase). The Company expects to extend the lease agreement ended in August 2021 for an additional five years. The Group also leases offices in Hong-Kong. The contractual period of the aforesaid lease agreement ended in February 2021. The Group also leases offices in the U.S. for a contractual period of three years, which ends in August 2023.
Lease payments	$ 1,118,000	1,095,000
Hong-Kong [Member]
Leases (Details) [Line Items]
Lease liability	3,660,000
Lease liability and right-of-use asset	$ 3,078,000
Vehicles [member]
Leases (Details) [Line Items]
Lease liability		106,000
Lease liability and right-of-use asset		$ 91,000

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease liability and right of use asset - Leases of offices [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases (Details) - Schedule of lease liability and right of use asset [Line Items]
Balance	$ 2,673	$ 1,891
Depreciation	856	842
Additions	1,421	1,624
Disposals	69
Balance	3,169	2,673
Buildings [member]
Leases (Details) - Schedule of lease liability and right of use asset [Line Items]
Balance	2,506	1,687
Depreciation	740	706
Additions	1,312	1,525
Disposals
Balance	3,078	2,506
Vehicles [member]
Leases (Details) - Schedule of lease liability and right of use asset [Line Items]
Balance	167	204
Depreciation	116	136
Additions	109	99
Disposals	69
Balance	$ 91	$ 167

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of maturity analysis of the group's lease liabilities - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases (Details) - Schedule of maturity analysis of the group's lease liabilities [Line Items]
Total	$ 3,766
Current maturities of lease liability	1,148	$ 1,055
Long-term lease liability	2,618
Not later than one year [member]
Leases (Details) - Schedule of maturity analysis of the group's lease liabilities [Line Items]
Total	1,148
One to five years [Member]
Leases (Details) - Schedule of maturity analysis of the group's lease liabilities [Line Items]
Total	$ 2,618

Transactions and balances wit_3

Transactions and balances with related parties (Details) - USD ($)	Jul. 07, 2020	Dec. 31, 2020
Transactions and balances with related parties (Details) [Line Items]
Share-based payment expenses		$ 16,666,000
Officers and directors [Member]
Transactions and balances with related parties (Details) [Line Items]
Grant of stock options	1,000,000
Exercise price	$ 0.70

Transactions and balances wit_4

Transactions and balances with related parties (Details) - Schedule of Balances with related parties - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Related parties [Member]
Transactions and balances with related parties (Details) - Schedule of Balances with related parties [Line Items]
Other payables	$ 207	$ 130

Transactions and balances wit_5

Transactions and balances with related parties (Details) - Schedule of Shareholder and other related parties benefits $ in Thousands	Dec. 31, 2020USD ($)		Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Schedule of Shareholder and other related parties benefits [Abstract]
Salaries and related expenses- related parties employed by the Group	$ 18,252	[1]	$ 1,047	$ 829
Number of related parties	5		4	4
Compensation for directors not employed by the Group	$ 2,204		$ 218	$ 311
Number of directors	6		6	7
[1]	Includes share-based payment expenses of $16,666,000, see note 17.B regarding warrants issued to the CEO.

Events after the reporting da_2

Events after the reporting date (Details) - USD ($)	2 Months Ended
	Feb. 28, 2021	Jan. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Events after the reporting date (Details) [Line Items]
Ordinary shares issued	74,100,000	74,100,000	4,179	1,931
Gross proceeds from the offering (in Dollars)	$ 833,000,000
Warrants [Member]
Events after the reporting date (Details) [Line Items]
Ordinary shares issued	1,137,500	1,137,500